

Review

Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy

Samuele Ferrari,¹ Erika Valeri,¹ Anastasia Conti,¹ Serena Scala,¹ Annamaria Aprile,¹ Raffaella Di Micco,¹ Anna Kajaste-Rudnitski,¹ Eugenio Montini,¹ Giuliana Ferrari,^{1,2} Alessandro Aiuti,^{1,2} and Luigi Naldini^{1,2,*}

¹San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy

²Vita-Salute San Raffaele University, Milan 20132, Italy

*Correspondence: naldini.luigi@hsr.it

<https://doi.org/10.1016/j.stem.2023.04.014>

SUMMARY

The growing clinical success of hematopoietic stem/progenitor cell (HSPC) gene therapy (GT) relies on the development of viral vectors as portable “Trojan horses” for safe and efficient gene transfer. The recent advent of novel technologies enabling site-specific gene editing is broadening the scope and means of GT, paving the way to more precise genetic engineering and expanding the spectrum of diseases amenable to HSPC-GT. Here, we provide an overview of state-of-the-art and prospective developments of the HSPC-GT field, highlighting how advances in biological characterization and manipulation of HSPCs will enable the design of the next generation of these transforming therapeutics.

INTRODUCTION

Ex vivo hematopoietic stem/progenitor cell (HSPC) gene therapy (GT) consists of the infusion of genetically modified cells that reconstitute the hematopoietic system with their engineered progeny and may rescue a disease pathophysiology up to a cure. HSPC-GT entails a multi-step process starting from the harvest of HSPCs from the patient or, more rarely, an immunologically matched healthy donor; followed by their *ex vivo* culture and genetic modification, whether achieved by gene transfer or gene editing (GE); and finally infusion into the patient, most often after administration of a conditioning regimen to allow efficient engraftment of modified cells (Figure 1).

Because conditioning depletes the resident HSPCs from the bone marrow (BM) to make space for the infused cells, it establishes a transient myelosuppression exposing the patient to the risk of infections and hemorrhages, as it occurs after autologous or allogenic HSPC transplantation (HSCT). The faster the hematopoietic recovery, the safer the treatment and the lower its morbidity.¹ Once full reconstitution has been achieved, long-term follow-up monitors stability of the transduced graft and its therapeutic benefits as well as the potential emergence of delayed adverse effects that can be traced back to the procedure.

Pioneering clinical trials of HSPC-GT were conducted on patients affected by primary immunodeficiencies using gene transfer vectors derived from murine gamma-retroviruses (γ RVs).^{2–5} Despite the low efficiency of gene transfer into human HSPCs, these studies provided early evidence of the substantial therapeutic benefit that can be achieved upon engraftment of even a small fraction of gene-corrected HSCs (i.e., the rare subset of HSPCs endowed with long-term self-renewing and repopulating capacity) and led to the market approval of the first *ex vivo* HSPC-GT.⁶ These studies, however, also highlighted the Achilles' heel of the strategy, as some patients later developed leukemia originating from HSPCs carrying vector insertion next to a

cellular proto-oncogene, leading to its overexpression and triggering its transforming potential.⁷ The ensuing quest for more efficient and safer gene transfer vectors was met by the advent of pseudotyped lentiviral vectors (LVs),⁸ which captured the proficiency of the Human Immunodeficiency Virus (HIV) at delivering its genetic cargo into the nucleus.

CURRENT STAGE OF CLINICAL DEVELOPMENT OF LENTIVIRAL HSPC-GT

The availability of a highly efficient gene transfer vector system has led to broader application of HSPC-GT in several diseases, including primary immunodeficiencies,^{9–14} metabolic diseases,^{15–18} hemoglobinopathies,^{19–21} and BM failures.²² As of 2020, four hundred patients had received HSPC-GT for the treatment of 14 diseases; 279 thereof had been treated with LVs in 34 trials.²³ Most LV-treated patients reported a substantial and sustained benefit from HSPC-GT thanks to high levels of engraftment with gene-corrected HSPCs. Current numbers are likely to be higher, considering that HSPC-GT products are now available on the market (for β -thalassemia [BThal] and cerebral adrenoleukodystrophy [cALD] in the USA and metachromatic leukodystrophy [MLD] in the EU) and other ones are in advanced stages of clinical development.

Autologous HSPC-GT may eventually position itself as first-line treatment for many monogenic diseases currently amenable to allogenic HSCT. Contrary to the immunological constraints of allogenic HSCT, HSPC-GT is available to every patient and does not entail the risk of developing graft-versus-host disease, which represents a major cause of morbidity and lethality. Given that partial chimerism with functional cells can be easily established with autologous gene-modified HSPCs, lower-intensity non-myeloablative conditioning regimens and emerging chemotherapy-free strategies sparing off-target tissues^{24–26} might be successfully employed to further reduce risks and morbidity in






Figure 1. Representation of the HSPC-GT process

AAV6, adeno-associated vector serotype 6; IDLV, integrase defective lentiviral vector; ssDNA, naked single-stranded DNA.

settings where correction of a fraction of HSCs provides the full benefit of the treatment.

Intriguingly, HSPC-GT has been shown to surpass the benefits of allogeneic HSCT in some lysosomal storage diseases, like MLD, because of the possibility to establish supra-normal expression of the functional enzyme in the transduced HSPC progeny, resulting in increased clearance of the stored toxic products and bioavailability of functional enzymes for the cross-correction of tissue resident cells.²⁷ This paradigm may be applied to an increasing number of metabolic diseases.^{15–18,28} Applications of HSPC-GT may extend outside of the field of genetic diseases and provide a new platform for targeted delivery of biotherapeutics to disease sites, such as tumors, by combining tissue-specific homing of selected HSPC progeny with advanced engineering of vector design for lineage- and context-specific transgene expression.^{29–31} Similarly, microglia-mediated gene delivery may be explored for the treatment of neuroinflammatory and degenerative diseases.

γ RVs and LVs integrate semi-randomly genome-wide,³² and vector Integration Sites (ISs) are distinctive genetic marks of each genetically modified cell and its progeny. Retrieval of ISs using powerful PCR-based techniques coupled to Next Generation Sequencing (NGS) and computational analyses enables detection, output tracking, and quantification of an abundance of thousands of clones from circulating blood cell types, tissues, or plasma serially harvested after GT.^{33–41}

Clonal tracking analyses in LV-based HSPC-GT clinical trials have revealed highly polyclonal and multilineage reconstitution of the hematopoietic graft without signs of expanding or dominant clones over several years of follow-up in most subjects.^{12,15,16,19,27,33–37} Longitudinal analyses of the clonal

repertoire from early to late phases of hematopoietic reconstitution showed that hematopoiesis is mainly sustained early after transplant by short-lived clones with output in one or few lineages,³⁸ which are exhausted over time and are replaced by more stable and multipotent progenitors bearing some of the expected features of HSCs. Furthermore, clonal tracking analyses allow the investigation of the dynamics and hierarchical relationships of progenitor subsets,³⁹ such as evaluation of their heterogeneity in the commitment to differentiate toward specific lineages and the presence of lineage-specific selective advantage in certain diseases.³⁶

Further studies may shed light on stability and long-term resilience of the engineered hematopoietic graft and whether the process of *ex vivo* genetic manipulation and/or the replication stress sustained upon hematopoietic reconstitution may induce excess accrual of mutations and endanger a risk of premature drift toward clonal hematopoiesis.⁴⁰ Moreover, insights into the factors regulating the choice between activation and latency among the infused HSCs and the establishment of a dormant reservoir of engineered HSCs to provide a response to stress conditions are lacking and remain invisible to current clonal tracking studies but would be important to further perfect transplantation strategies.

Additional platforms for gene addition have been developed from naturally occurring and engineered DNA or RNA transposases on the premise of lower costs and potential advantages from the non-viral origin and integration site preferences.^{41,42} Currently, however, their clinical development has been mostly confined to lymphocyte engineering.⁴³ Further studies exploring the possibility to engineer them for site-specific integration may unleash the full potential of these platforms.




Figure 2. The gene editing tools and the intended outcomes of their activity
Italic descriptions mean that reports showing these outcomes in human HSPCs are currently lacking.

STATE-OF-THE-ART AND EMERGING GENE EDITING PLATFORMS

Designer nuclease-based editing

In the last two decades, the GT toolbox has been enriched with several new programmable chimeric molecules enabling site-specific gene editing (Figure 2).⁴⁴ Designer nucleases, such as Zinc Finger (ZFN), Transcriptional Activator-Like Effector (TALEN), megaTAL, and CRISPR-Cas nucleases, are composed of a customizable DNA binding module (either consisting of a protein domain or a guide RNA [gRNA]) and a catalytically active domain triggering DNA double-strand break (DSB) formation upon successful recognition of the target sequence by the binding module. The DNA DSB engages the DNA repair pathways that ultimately result in permanent installment of the intended genetic modification of the target site.⁴⁵ Faithful reconstitution of the native sequence is not a favored outcome, as it is subject to another round of cutting by the nuclease. Instead, ligation of DNA ends often exploits the error-prone non-homologous end-joining (NHEJ) and other alternative pathways (e.g., microhomology-mediated end-joining [MMEJ]), introducing small nucleotide insertions and deletions (indels) at the target site that can be expected to compromise recognition by the DNA binding module.

Cells engaged in S/G2 cycle phases may also repair the DNA DSB by high-fidelity homology-driven repair (HDR) in presence of a DNA bearing sequence homology to the cut site. HDR may be exploited to integrate an arbitrary sequence in a precise genomic location, thus overcoming the main limitation of integrating vectors. Thus, exogenous DNA templates carrying the intended new sequence to be pasted into the locus must be provided for HDR editing. According to the size of the intended edit, this can be accomplished with naked single- or double-stranded DNA (ss/dsDNA)^{46,47} or by using a viral vector, such as Adeno-Associated Vector 6 (AAV6)⁴⁸ or Integrase-Defective LV (IDLV).^{49,50}

Eukaryotic cells deploy a composite DNA damage response (DDR) to deal with DNA DSBs induced by exposure to radiations or chemicals.⁴⁵ These pathways scan for free DNA ends and converge on the tumor suppressor p53, which slows down cell proliferation while promoting attempts at repairing the DNA lesions and ultimately instructs cell fate among survival, differentiation, senescence, or apoptosis depending on the damage burden and the success or failure of DNA repair.⁴⁵ Similarly, one or few nuclease-induced DNA DSBs can trigger p53-dependent DDR in HSPCs, which decreases their reconstitution potential and graft clonal diversity in xenograft models.⁵¹ As the DNA

DSB load increases, such as in the presence of nucleases with poorer specificity, the DDR burden becomes unsustainable, leading to the establishment of inflammatory transcriptional programs, protracted proliferation arrest, or apoptosis and severe impairment of HSPC clonogenic capacity. Because the DDR triggered by DNA DSB may cumulate with that induced by additional editing components (such as the DNA template^{51–53}) and *ex vivo* culture per se, minimizing its induction and dampening the downstream consequences by optimizing nuclease specificity and transiently inhibiting p53,^{51,54} respectively, might be considered for therapeutic GE.

Engineering of the designer nucleases and optimization of their delivery enabled highly efficient editing of several target sites, reaching nearly full NHEJ-mediated disruption of functional sequences, such as open reading frames and regulatory elements, in human HSPCs.^{55,56} Of note, targeted gene knockout/knockdown by disruption of a coding sequence is an outcome precluded to integrating vectors (with few exceptions²¹). Conversely, since long-term repopulating HSCs rarely enter and slowly progress into the cell cycle, targeted integration of long-range therapeutic sequences by HDR is disfavored. Despite the considerable efforts in enhancing its efficiency by optimizing culture conditions,^{49,57,58} promoting cell-cycle progression and/or favoring HDR,^{54,59–61} and choosing the most appropriate delivery vehicle for the DNA template, HDR editing remains challenging.^{46,47,50,52,53} Most promising data in xenograft models show that <30% of long-term engrafting HSCs can be edited by HDR using viral template delivery in the absence of selective advantage or enrichment of modified cells,^{54,58,62} which currently constrains prospective HDR application to diseases where therapeutic efficacy and favorable risk/benefit balance can be attained by correcting a minority of the cells. Recent advancements in the design, quality, and delivery of long non-viral DNA templates (ssDNA, dsDNA, and mixed ss/ds DNA carrying Cas recognition sites) enabled promising results in terms of editing efficiency in some differentiated hematopoietic cells, but <10% in bulk HSPCs *in vitro*.^{47,63} Of note, when an HDR strategy targets an exon, such as to correct a mutation or to knock in a functional complementary DNA (cDNA) correcting all downstream mutations, it is also relevant to consider the potential adverse effect of NHEJ/MMEJ on the remaining non-HDR edited alleles, whose genetic inactivation may convert dysfunction to loss of function, such as in sickle cell disease (SCD) or in haploinsufficiency disorders such as GATA2 deficiency, RUNX1 deficiency, and Diamond-Blackfan anemia. Due to these challenges, HDR-mediated gene editing lags behind NHEJ-mediated disruption in terms of clinical development, with the latter reporting promising and reproducible efficacy in recent clinical trials for hemoglobinopathies⁶⁴ and expected to reach marketing authorization in the upcoming years.

Nickase-based base and prime editing

Base and prime editors (BEs/PEs) are more recent genome engineering tools composed of a sequence-specific DNA binding and nicking module (i.e., delivering a single-strand DNA break [SSB]), typically derived from Cas, fused to constitutively active enzymatic domains, such as deaminases or reverse transcriptases, bearing specific activities on nucleic acids.⁶⁵ Of note, the activity of some of these editors depends on or is highly

improved by simultaneous inhibition of endogenous repair pathways (e.g., the base excision or the mismatch repair) to reach therapeutically relevant editing efficiencies.^{66–68} BEs/PEs can generate more homogeneous genetic outcomes at the target site compared to nuclease-based approaches and can bypass the requirement for DNA DSB and restriction of cell-cycle phases. Their application, however, is mostly limited to installation of short-range edits (A•T>G•C transition by adenine BEs, C•G>T•A transition by cytosine BEs, or all possible insertions/deletions/substitution by PEs) and requires the design of mutation-specific gRNAs when aiming for targeted gene correction, constraining their use outside of diseases for which mutation-specific correction is sustainable for drug development. Recent advancements of the PE technology may enable the installation of longer edits—either deletions, replacements, or insertions—by concurrently delivering pairs of prime editing gRNAs (pegRNAs) or by introducing short target sequences acting as substrates for a successive round of DNA manipulation mediated by site-specific recombinases or integrases.^{69–72}

Adenine BEs have reached tolerated and therapeutically relevant editing in human HSPCs,^{73–76} prompting clinical investigation of this technology for the treatment of hemoglobinopathies (NCT05456880). Conversely, cytidine BEs have shown lower efficiency and little application in HSPCs so far.⁷⁷ Short-range PE has been recently reported in an SCD mouse model by forcing *in vivo* selection of prime-edited cells and at low efficiency in human HSPCs *in vitro*.⁷⁸ Furthermore, the feasibility of successfully and safely applying the emergent multi-component PE versions requiring concurrent or sequential steps of complex genetic engineering is questionable and still remains to be demonstrated in HSPCs.

Finally, the possibility to stably switch off/on expression of a target gene by modifying its local epigenetic features also emerged as a DNA break and mutation-free approach. Hit-and-run delivery of a combination of DNA methyltransferase and transcriptional repressor coupled with a sequence-specific DNA targeting domain can instruct stable repression of a targeted locus with high specificity and tolerability in eukaryotic cell lines.^{79,80} The application of this platform to relevant primary target cells is being explored to provide an alternative for less harmful and multiplexed engineering.

Emerging editing platforms and prospective improvements

All editing platforms undergo constant evolution toward higher efficiency, specificity, and genome accessibility by discovery of new enzymes and generation of novel variants through rational design and forced evolution.^{81–90} Researchers can now choose from an ever-growing armamentarium of editing tools with different breadths of genomic coverage and distinct on-/off-target activities. Some efforts have also been made to enhance specificity and efficiency of DNA/RNA transposons from different species,^{91–94} however, they have only reached proof-of-principle in prokaryotes or eukaryotic cell lines. At the present time, HDR editing remains the only viable option for long-range editing and targeted integration of full expression cassettes in human HSPCs, despite its complexity and the limitations of the process.

Ex vivo delivery of editors into HSPCs is mostly achieved by electroporation of their *in vitro* synthesized RNA or

pre-assembled ribonucleoprotein complexes (RNPs) in the case of RNA-guided Cas-based editors.^{95–97} This procedure allows robust pulses of expression, reaching high enough cellular concentration to allow efficient processing of the intended genomic target but limiting prolonged and iterative action on on-/off-target sites. Alternative delivery methods, such as lipid- (LNPs) or polyplex-based nanoparticles encapsulating RNA/RNPs, are being explored with the promise of lower toxicity and improved versatility.⁹⁸

GENOTOXIC RISKS OF HSPC-GT

Modification of the human genome comes with an intrinsic genotoxic risk. Vector-mediated insertional mutagenesis and undesired on-/off-target editing activity represent possible genotoxic mechanisms leading to expansion of a clone bearing growth-promoting mutations and paving the way to subsequent accumulation of synergistic mutations, eventually leading to leukemia. This sequence of events may occur in different circumstances, such as aging or exposure to mutagenic drugs, and manifest with variable time courses. Vector insertion and undesired GE events may represent the first trigger, with the likelihood and timing of further progression to transformation being dependent on stochastic and disease-related factors or occurring on a pre-existing clone, accelerating its evolution to full-blown malignancy. The proliferative demand of regenerative hematopoiesis in conditioned patients may favor selection and expansion of clones bearing gain-of-function mutations as well as result in replication stress leading to further accumulation of mutations impacting fitness, long-term stability, and leukemogenesis risk of the cell graft. While similar conditions apply in conventional HSCT, the possible impact of *ex vivo* manipulation on the total amount and quality of infused HSPCs may aggravate this risk. Ongoing studies tracking the rate of accumulation of somatic mutations in hematopoietic cells upon HSPC-GT will provide insights and compare it to HSCT.^{99–101}

Risks associated with gene transfer

Because of the high numbers of HSPCs receiving one or more vector insertions semi-randomly distributed across the genome, it is expected that the integrome of an HSPC-GT product nearly covers the accessible genome, including proto-oncogenes and tumor suppressor genes. The genotoxic risk of such insertions depends on whether they cause alterations in the expression level and/or messenger RNA (mRNA) structure of the targeted genes, resulting in activation of the oncogene transforming potential or inactivation of the tumor suppressor gene. The likelihood that an IS deregulates transcription of nearby genes depends on multiple factors. *In vitro* cell immortalization assays^{102–104} and *in vivo* oncogenicity studies in sensitized tumor-prone mouse models^{105–107} showed that vector design is the most important factor impacting genotoxicity. γ RVs and LVs with transcriptionally active Long Terminal Repeats (LTRs) show a higher risk of genotoxicity, as they can proficiently alter expression of the targeted genes by aberrant transcription originating from LTRs or activation of endogenous promoters by interaction with the strong vector LTR enhancers. A preferred vector design thus enforces deletion of transcriptionally active sequences from both LTRs upon reverse transcription and inte-

gration of the proviral form (Self-Inactivating [SIN] vectors)¹⁰⁸ and has proven significantly less genotoxic than earlier versions in preclinical genotoxicity assays^{102–107} and several clinical trials.²³ However, SIN vectors must comprise an internal promoter to express the transgene, preferably taken from a cellular gene with either housekeeping function and moderate ubiquitous expression or lineage-specific expression, both of which reduce the potential for enhancing transcription of nearby genes in HSPCs. In addition, while both γ RVs and LVs preferentially integrate into the open chromatin of expressed genes, they show distinct biases for some genomic features (i.e., the preference of γ RV for insertion near active promoters),³² affecting the risk of enhancer-mediated genotoxicity.

As SIN vectors may harbor cryptic splice sites, they may occasionally alter the mRNA structure of a host gene within which they have been inserted and induce premature termination or interfere with splicing.^{109–111} While the genotoxic risk of such mechanisms is likely low for commonly used LVs, its occurrence has been advocated in two different HSPC-GT clinical trials for BThal and X-linked Severe Combined Immunodeficiency (SCID-X1).^{11,112,113} In these trials, vector integration triggered HMGA2 overexpression and expansion (but not full transformation) of the clones bearing this IS. In another HSPC-GT developed for cALD, the SIN LV was designed to comprise a strong internal promoter derived from a γ RV LTR (MND) to drive robust expression of the transgene product. Long-term follow-up reported clonal expansion and emergence of myelodysplastic syndrome (MDS) in three patients, likely due to insertional activation of the *MECOM* oncogene.^{18,114,115} Of note, despite the documented risk of delayed adverse events, the severity of cALD and the substantial benefit provided by HSPC-GT may outweigh the risk of malignancy, according to FDA approval of the therapy. Thus, while the most used LV backbones have shown excellent long-term safety in a growing number of patients and diseases, attention to changes in vector design remains paramount to continue granting it. Incorporation of additional features such as chromatin insulators may alleviate the residual risk of enhancer-mediated transcriptional deregulation near the IS;^{106,116} despite its impact on the overall safety and proficiency of the vector, its effect on the regulation of the genomic region harboring the IS must be carefully evaluated, and its relevance in the context of HSPC-GT has yet to be evaluated.

Besides the risk of malignant transformation, vector-mediated oncogene activation in HSPCs could trigger the activation of cellular senescence.^{117,118} However, whether treatment-induced senescence may broadly affect hematopoietic reconstitution and functionality across HSPC-GT applications remains to be investigated.

Risks associated with gene editing

In principle, nuclease-based GE strategies allow for higher levels of specificity compared to semi-random integration of viral vectors. Despite the technological advances and the constant amelioration of nuclease specificity, DNA DSBs at genomic on-/off-target sites still represent the major potential source of genotoxicity for clinical applications. Depending on the genomic location, off-target DNA DSB generation may lead to inactivation of tumor suppressor genes, off-target incorporation of the transgene, or chromosomal rearrangements^{119–121} (Figure 3). A




Figure 3. Schematics of the potential genotoxic events occurring at on-/off-target sites upon GE with different platforms

Shadowed drawings and descriptions mean lower likelihood of the editing event to occur compared to other platforms. Italic descriptions with question marks mean that these editing outcomes are only suspected but not yet proven.

growing armamentarium of cell-free and *in cellula* assays as well as *in silico* prediction algorithms were developed to identify putative off-target sites in edited cells.^{122,123} Specificity assessment of an editor starts from a thorough bioinformatic analysis verifying the unique occurrence of the target sequence and its most homologous permutations, followed by an experimental analysis usually performed in two steps. The first step aims to identify the most comprehensive panel of putative off-targets in an unbiased and highly sensitive manner, and it is usually performed using two orthogonal techniques, challenging the editor with chromatin/DNA *in vitro* and/or by transfection into human cells. These methods usually yield a high number of putative off-targets, often only partially overlapping among different methods. In this context, several studies are thus aiming to identify the combination of assays and tools providing the highest sensitivity and specificity for off-target site calling while minimizing false positive and false negative rates.^{124,125} The calling of putative off-target hits within a validated tumor suppressor gene might kill the candidate nuclease, as biallelic targeting is a realistic possibility when using gene editing tools at variance with gene transfer vectors that may inactivate one allele by random integration but would hardly hit both within the same cell. The next step in the specificity assessment is then to interrogate by targeted deep-sequencing as many top-ranking candidates as feasible in the cell type of interest because specific cellular features may impact the off-target profile.¹²⁶ The nuclease delivery method and the duration of editor expression may also influence specificity,¹²⁷ and thus the second step of the analysis should be performed in conditions closely recapitu-

lating those intended for manufacturing the therapeutic product. These analyses have a sensitivity threshold ranging between 0.1% and 1% and will be blind to any off-target activity occurring at a lower rate. Because, similarly to gene transfer, a typical HSPC-GT product comprises hundreds of millions of cells, the occurrence of rare events remains possible and uninvestigated, and this uncertainty must be considered when performing risk assessment of any new procedure. Moreover, interindividual variability in the human genome may affect the off-target profile, thus adding another layer of complexity in specificity analyses and off-target validations.^{128,129}

While most scientific efforts have been focused on identifying and mitigating nuclease off-target activity by increasing specificity, recent evidence also pointed to a previously unappreciated on-target genotoxicity risk, mainly associated with loss of genetic material. Indeed, Cas cleavage could also generate long-range deletions (from >200 up to several thousand base pairs [bp]) and large insertions (≥ 50 bp) at the cut site in human cell lines and primary cells, including HSPCs.^{50,119,130–135} Moreover, chromosomal translocation events between on- and off-target sites have been shown in human HSPCs and non-human primate (NHP) models, sometimes even persisting *in vivo*.^{51,124,136} Sporadic occurrence of extensive rearrangements of one or few targeted chromosomes upon Cas9 cleavage, resulting in the formation of micronuclei, chromosomal bridges, and aberrant nuclear structures, known as chromothripsis, has also been reported.^{137,138}

For HDR editing, another factor to take into consideration is the risk of on-/off-target insertion of the DNA template, as shown

for AAV inverted terminal repeats (ITRs), which are trapped in human HSPCs at a relatively high rate, including in long-term engrafting clones in xenografts.⁵⁰ While this may often be inconsequential, AAV ITRs exhibit transcription-promoting activity, and AAV integrations have been occasionally associated with carcinogenesis in some animal models.^{139–143} In addition, integration of viral vector fragments may happen in randomly occurring DSBs located at sites of slow/altere DNA replication rate, such as chromosomal fragile sites.¹⁴⁴ IDLV as a DNA template appears less prone to fragmentation,⁵⁰ albeit not exempt from trapping of its full-length sequence, partially reducing heterogeneity of genetic outcomes and the genotoxic risk of on-/off-site integration due to the presence of SIN LTRs.¹⁰⁸ Instead, the integration profile of ssDNA and dsDNA as HDR templates has not been investigated yet. Overall, the potential issues arising from off-target integration of a DNA template should be taken into account when designing the therapeutic cassette comprised therein.

Some unwanted consequences of nuclease-mediated GE may be mitigated by BEs and PEs (Figure 3), as they aim to conserve the continuity of the DNA at the target site. However, a comprehensive assessment of BE and PE specificity and safety in HSPCs is still missing. Indeed, BEs might raise additional safety concerns arising from the constitutive activity of the deaminase domains that may cause semi-random and gRNA-independent deamination at genomic susceptible sites, such as R-loops, and on the RNA, as shown in cell types different from HSPCs.^{145–148} Similarly, further studies are needed to address the putative, but still unproven, potential genotoxic risk of PE due to transient expression of its reverse transcriptase module and eventual inhibition of DNA mismatch repair in PE4 and PE5 systems^{66,67} in HSPCs. Furthermore, the SSB generated by the nickase domain of BE may be converted into DSB during DNA replication and eventually result in the adverse consequences discussed above, albeit to a significantly lesser extent compared to designer nucleases. Moreover, indels are introduced at the target site to some extent by the staggered double nicking delivered by PEs (particularly with PE3 and PE5 systems), again raising the risk of DSB generation and its unintended consequences,^{149,150} such as tandem duplication, prime editing gRNA scaffold incorporation, long-range insertions/deletions, translocations, and LINE-1 transposable element subfamily integration.^{66,70,151–153} Of note, considering the high number of HSPCs to be treated and infused, an even lower frequency of potentially genotoxic editing events might still be problematic when aiming for clinical translation of HSPC GE.

Currently, none of the existing GE platforms fully accomplish the promise of seamless genetic engineering devoid of genotoxic risk in HSPCs. Preclinical assays predicting whether any newly assembled or further evolved GE tool might turn into excessive genotoxic burden and outweigh the expected benefits would be highly relevant. The predictive power of *in vitro* cell immortalization assays and *in vivo* oncogenicity studies in tumor-prone mice is thus limited by the poor flexibility of the mutagenic input of the former and the challenge against a genome different from the human one for the latter, ultimately hampering inference on genotoxic risk related to a designer editor. Aberrant expansion or altered growth/differentiation properties of one or more human HSPC clones in xenograft models from an initially

polyclonal product is the most advanced experimental setting able to readout intrinsic genotoxic risk of the procedure due to the accrual of gain-of-function mutations prodromic to cell transformation.¹⁵⁴ Longitudinal tracking of HSPC clones may be pursued by retrieving indels⁵⁶ or degenerated molecular identifiers^{54,155,156} introduced at the target site by nuclease-mediated editing. In the absence of such a possibility, pre-labeling edited HSPCs with barcoded LVs or reconstructing clonal phylogeny by accumulation of somatic/mitochondrial mutations¹⁵⁷ may be alternative options for preclinical assessment of potential treatment-related adverse effects on clonal outgrowth in a recipient. Clonal tracking studies in NHPs may be important to further validate the impact of novel gene editing technologies on HSPC biology at preclinical level.^{56,158}

THE IMPACT OF EX VIVO CULTURE ON HSC BIOLOGY

Ex vivo activation is still a prerequisite to reach sufficient levels of HSPC genetic engineering for clinical applications. Culture conditions have been tailored over the past decade to ensure high gene transfer and GE efficiencies and preservation of some long-term repopulating capacity of HSCs upon manipulation.^{49,159,160} While γ RV gene transfer is strictly dependent on proliferation of the infected cells, LVs bypass this requirement, but activation of HPSCs from the resting condition is required for efficient transduction, usually achieved upon three days of culture in stem-preserving and early active cytokine medium.¹⁶¹ Recently, transduction enhancers (see "Investigating and overcoming HSPC responses to gene transfer and GE") enable the generation of high proportions of genetically engineered HSPCs by one instead of two cycles of LV transduction, thus shortening time in culture,¹⁵ with the resulting cell products yielding faster hematopoietic reconstitution and fully transduced hematopoietic grafts in patients.¹⁵ Current GE protocols are also designed on three to four days of culture to activate HSPCs^{160,162–170} and, in the context of HDR editing, require full progression of the most primitive cells to S/G2 phase of the cell cycle to achieve a sizable fraction of edited cells in long-term grafts.^{49,54,57,58} Even if these relatively short culture times may allow no more than one/two cell divisions of the rare HSCs, emerging evidence suggests that they may elicit cellular responses negatively impacting the activity and content of long-term multilineage repopulating progenitors.^{160,171,172} While physiologically in a quiescent state, HSCs in culture are forcibly pushed out of their dormant state and may eventually accumulate DNA damage^{173,174} and spontaneous mutations or chromosomal abnormalities,¹⁷⁵ ultimately resulting in premature exhaustion and repopulating dysfunctions. Indeed, activated HSPCs produce reactive oxidative species (ROS) and may establish an aged-like phenotype with overt myeloid skewing.^{99,176–183} Culture stress may be further exacerbated during genetic engineering because of the p53-mediated DDR activation, overall leading to cell differentiation, loss of engraftment of early progenitors,^{171,184} and reduced graft clonality.⁵⁴

Despite all of the above, clonal tracking studies in humans provide evidence that HSCs that have been cultured *ex vivo* for a few days and genetically engineered by viral gene transfer have the potential to robustly engraft and sustain multilineage hematopoietic reconstitution for decades.¹ Consistently, the longer the time

in culture, the higher potential impact on the content of HSCs in the product and consequently on the clonal repertoire of the genetically engineered graft and possibly on their capacity for multilineage output. Whether an oligoclonal input of the hematopoietic graft may constrain its long-term resilience may depend on the capacity of engrafted HSCs to undergo robust symmetric self-renewing divisions *in vivo*, which escape detection by current clonal tracking studies. Intriguingly, reports of spontaneous single clone somatic reversion of some genetic deficiencies leading to sustained mosaicism with functional reconstitution of hematopoietic lineages and significant therapeutic benefit would support this contention.^{185–188}

Of note, experimental studies of human HSPCs have been mostly conducted by transplantation experiments in xenograft models,^{189,190} which are limited in capturing the full spectrum of HSPC multipotency^{191,192} due to the lack of a humanized niche as well as the short time window of analyses. The advent of single-cell omics technologies^{181,193} and advanced single-cell-derived colony forming assays^{99,194–196} enable comparative characterizations of the properties of bona fide HSCs and committed progenitors; however, none of this emerging biology has been integrated yet into innovative culture systems to capture and preserve HSCs for genetic engineering. The recently developed map of genes and signaling pathways identified during HSC ontogeny in human embryo may uncover additional instructions to keep fully functional HSCs *in vitro*^{197–199} and/or enable efficient differentiation of human pluripotent stem cells into bona fide HSPCs.^{199–201}

Significant efforts have been directed toward the identification of compounds that could promote expansion of a CD34⁺CD90⁺ population enriched for phenotypic HSCs displaying long-term repopulating activity in limiting dilution *in vivo* assay.^{160,162,165,202} The definitive proof that these culture conditions can expand, rather than maintain primitive long-term HSCs while promoting the proliferation of short-term multilineage progenitors, remains to be achieved. Recently, cytokine-free culture conditions have been shown to support robust human HSC expansion *ex vivo*.²⁰³ In addition, attempts to reproduce mechanical and niche-dependent signals may mitigate culture-induced stress responses to improve preservation or achieve successful HSC expansion for genetic engineering.²⁰⁴ A combination of innovative expansion conditions coupled to multi-omics single cell transcriptional/epigenetic profiling and advanced 3D culture systems may provide a quantitative and qualitative assessment of *ex vivo* cultured HSCs that is predictive of their long-term functionality upon genetic manipulation. These advances may eventually bring into reach the long-sought goal of truly expanding HSCs *ex vivo*, opening the way to the possibility of selecting cells bearing intended genetic edits.

INVESTIGATING AND OVERCOMING HSPC RESPONSES TO GENE TRANSFER AND GE

All gene transfer and GE technologies expose cells to exogenous nucleic acids and/or viral vectors. Innate immunity and nucleic acid sensors might thus affect the cellular response and efficiency of genetic manipulation.²⁰⁵

Pattern recognition receptors (PRRs) recognize evolutionarily conserved structures on pathogens (pathogen-associated molecular patterns) within the specific compartments that they

patrol. Engagement of Toll-like receptors or the cytosolic nucleic-acid-detecting immune receptors, such as the RIG-I family of helicases (RIG-I, MDA5, and LGP2) and the DNA sensors cGAS, IFI16, or AIM2, will ultimately elicit type-I interferon (IFN)-mediated antiviral responses.^{206–208} HSPCs express a variety of these PRRs that enable them to detect and respond to foreign pathogens or endogenous damage.²⁰⁵ In the context of viral gene transfer, substantial differences have been observed in HSPCs in response to distinct vectors. γ RVs, but not LVs nor AAVs, trigger IFN-stimulated antiviral genes.¹⁷¹ HIV-derived LVs likely benefit from mechanisms of active innate immune evasion that the parental virus evolved to avoid cGAS/STING-dependent sensing of the viral nucleic acids within the cytosol.²⁰⁹ In the context of GE, exogenous RNA used to express the editor, as well as gRNA, are recognized in the cytosol by the RIG-I pathway and trigger a wave of type I IFN responses.^{97,210} Removal of the 5'-triphosphate from gRNA and *in vitro* RNA synthesis using modified nucleotides^{211,212} alleviates inflammatory signaling and some of the consequent detrimental responses to GE.

For LVs and AAVs, it is the vector DNA that is sensed within the HSPC nucleus, likely through reverse transcription or replication intermediates, respectively, that mimics the ends of broken DNA and leads to activation of p53-mediated DDR.^{50,171} Transient curtailing of vector-mediated activation of these p53-dependent responses significantly improves engraftment and clonality of genetically manipulated HSPCs.^{50,51,54} This may be particularly relevant when aiming for HDR editing, given the convergent impact of template viral vector sensing and DNA DSB on DDR.^{51–53} Such an adverse response might have contributed to the severe delay in engraftment recently reported for the first SCD patient receiving HSPCs treated by AAV6-mediated HDR editing (<https://ir.graphitebio.com/press-releases/detail/84/graphite-bio-announces-voluntary-pause-of-phase-12-cedar>). Whereas one may raise concerns for suppressing, albeit transiently and incompletely, the p53-dependent genome integrity keeper and tumor suppressor pathways, this strategy may prevent both an overall clonal loss and the selection of clones bearing or spontaneously acquiring *TP53* genetic inactivation during the manufacturing process.^{213–215} Of note, short ssDNA templates have been reported to avoid activation of p53-dependent DDR,^{51–53} while little is known about longer ss/dsDNA.

Electroporation, however, may come at the cost of significant toxicity, which may lead to acute loss of viability and transient growth arrest, although followed by recovery of surviving cells.⁵⁴ Indeed, electroporation per se may activate DDR, inflammatory responses, transient growth arrest, and apoptosis in a fraction of treated HSPCs.⁵⁴ As LNP-based delivery gains more foothold in the field, it will be important to address potential innate immune activation elicited by components of these particles and their nucleic acid or protein cargos in the context of HSPC genetic engineering.

Cellular recognition of exogenous components may also constrain the efficiency of genetic manipulation in human HSPCs. Some antiviral type-I IFN inducible host factors (restriction factors) are highly expressed at steady state in HSPCs.²¹⁶ The IFN-inducible antiviral protein IFITM3 was identified as a potent restriction block to LV gene transfer in HSPCs,²¹⁷ which can be overcome through molecules such as Cyclosporin H (CsH),²¹⁷ Rapamycin,²¹⁸ or Resveratrol,²¹⁹ significantly enhancing

gene transfer. The potential benefit of transduction enhancers is best shown by the improved clinical success rate of BThal and SCD HSPC-GT achieved by modified gene transfer protocols, including some small molecules increasing LV uptake and integration in HSPCs, such as poloxamers and prostaglandin E2 (PGE2),^{35,220} respectively. Of note, the increased transduction levels obtained by these enhancer combinations are much higher when measured *in vitro* in the infused drug product than *in vivo* in xenograft models^{221,222} or in cells harvested from HSPC-GT patients.^{35,220} This suggests that PGE2 and poloxamers may preferentially enhance transduction of short-term progenitors versus long-term repopulating HSCs, highlighting the challenge of accurately measuring gene transfer in the clinically relevant HSC compartment versus bulk manipulated populations through simple assays amenable for Chemistry, Manufacturing, and Controls (CMC) development. As single-cell technologies become more affordable, analysis of transduction levels within HSCs could also become feasible for drug products, potentially improving their predictive value for long-term clinical efficacy. Significant donor-to-donor variability remains a challenge that does not seem to be overcome by these enhancer combinations. While the determinants of donor variability remain unclear and likely involve several parameters, differential expression of antiviral factors such as IFITM3 or TRIM5 correlates with transduction efficiencies in individual donors.^{217,223} CsH may overcome, at least in part, donor variability during HSPC-GT,²¹⁷ potentially representing an additional major benefit for the achievement of more standardized medicinal products.

THE IMPACT OF STEM CELL SOURCE, DISEASE BACKGROUND, AND CONDITIONING REGIMEN ON HSPC-GT

Beyond genetic modification, the clinical outcome of HSPC-GT depends on several factors, including stem cell source, patient's clinical condition, dose and quality of the cell product, status of the recipient BM microenvironment, and conditioning regimen.^{1,224}

HSPC source and harvest

Cell number and quality of collected HSPCs are critical parameters for ensuring fast hematopoietic recovery and long-term stability of HSPC-GT, also considering the loss upon manipulation and the amount required for quality controls. Mobilized peripheral blood (MPB) HSPCs have become the preferred source for patients undergoing HSPC-GT due to the reduced invasiveness and the higher numbers of HSCs collected, which reduces age-related and individual variability associated with BM HSPC harvest.^{19,35,225,226} Mobilization of HSPCs in GT trials is currently based on Granulocyte-colony stimulating factor (G-CSF) administration, usually in combination with the CXCR4 antagonist Plerixafor.^{18,19,35} Of note, G-CSF administration is avoided in specific disease settings, such as SCD, because of potential life-threatening complications. In line with HSCT results,^{225,227} MPB HSPCs showed faster myeloid reconstitution and increased transduced cell chimerism in the BM, leading to higher clonal composition of the engrafted stem cells and increased correction of mature myeloid populations with respect to patients treated with BM-derived HSPCs.^{36,228} Differences in cell

state and HSPC composition might explain the distinct behavior *in vivo* of the two sources,^{229–231} as the higher proportion and number of myeloid and primitive progenitors in MPB HSPCs correlated with earlier neutrophil recovery and higher transduced cell chimerism in the long term.²²⁸ HSPC collection still presents challenges in certain pathological conditions with low HSC content, heavily pre-treated patients, or low-body-weight pediatric subjects. *In vitro* expansion protocols^{162,165,202} are an attractive strategy to address these hurdles.

The impact of disease background

The disease background can impact the source and composition of the HSPC harvest as well as their behavior after transplantation. For instance, in bone marrow failure syndromes, cells are often more fragile and susceptible to culture stress. In other cases, disease features confer selective survival and/or growth advantage to the corrected cells, such as those occurring in Adenosine Deaminase (ADA)-SCID and Wiskott-Aldrich (WAS) for lymphoid cells,^{10,13} in WAS for platelets,^{13,232} in BThal and SCD for erythroid cells,^{233,234} and in Fanconi anemia for HSPCs.²² In these contexts, therapeutic benefit may be achieved even at low chimerism of transduced HSPCs and with avoidance or reduction of the intensity of the conditioning regimen, as shown for Fanconi anemia HSPC-GTs, in which a limited input of gene-corrected HSPCs infused without conditioning progressively expanded in the BM, eventually rescuing hematopoietic output in the periphery.^{22,235,236}

Recent studies highlighted that HSCs and BM niche components are altered in BThal and SCD^{237–239} and that targeting the identified defects can rescue the impaired HSC-BM niche crosstalk.²⁴⁰ Chronic inflammation is a key component in SCD pathophysiology, and increased inflammatory cytokines were reported to alter components of the BM microenvironment, such as osteo-lineage and endothelial cells, in SCD mice.^{241,242} Exposure to inflammatory signals and infections triggers the activation of HSCs by acting on cycling properties, DNA damage, and long-term self-renewal^{243–245} and can also injure BM niche populations. Impaired HSC function, as well as defective supporting activity by niche components, might be the cause of the low levels of genetically modified HSPCs long-term engrafted in some patients experiencing a lack of clinical benefit in recent HSPC-GT trials,^{19,20,35} although the root causes have not been clarified yet. BM niche defects may be further exacerbated by potential damage to hematopoietic and stromal components upon myeloablative conditioning, compromising their supportive capacity. Deeper knowledge of the BM and HSC features in inherited hematological disorders may ameliorate HSPC-GT outcomes by targeting specific niche defects before and/or after transplant and by tailoring conditioning regimens.

Disease background may also impact the risk of insertional mutagenesis, as shown by comparing the incidence of vector-induced leukemias in three early γ RV-based HSPC-GT clinical trials for WAS, SCID-X1, and ADA-SCID.²³ While WAS patients developed several myeloid and lymphoid dominant clones in their hematopoietic graft, eventually leading to MDS and/or T-Acute Lymphocytic leukemia (T-ALL), SCID-X1 patients developed only T-ALL or T cell lymphoma with lower incidence, and ADA-SCID patients showed even safer outcomes, with only one patient reported to develop T-ALL in the long-term

follow-up.²³ The specific biological activity of the transgene product and the potential consequences of its absence or de-regulated expression upon HSPC-GT may affect the likelihood of expansion and progression to transformation of clones bearing genotoxic ISs.^{246–248} Some diseases may also increase the risk of cell transformation without necessarily involving a causal role of vector insertions. In a recent HSPC-GT clinical trial for SCD, two patients developed MDS and acute myeloid leukemia (AML).^{220,249} For both adverse events, the role of vector insertions was eventually dismissed, as the blasts did not contain the vector in one case, and in the second case, vector ISs targeted the *VAMP4* gene, which is unrelated to cancer and was not de-regulated.^{250–252} Therefore, it appears that the well-documented increased risk of development of MDS and AML in SCD patients could be the underlying cause of the malignancies observed in HSPC-GT for this disease.^{253–255}

Tailoring the conditioning regimen to maximize HSPC engraftment and prevent adaptive immune responses

To achieve sufficient and stable engraftment of gene-corrected HSPCs, patients undergoing HSPC-GT often receive a chemotherapeutic conditioning regimen, whose intensity and type can be tailored to reach a minimal efficacious therapeutic target level while reducing toxicity.²⁵⁶ Myeloablative doses are necessary when high levels of engraftment are needed; specific tissue targeting, such as the brain, may further constrain the regimen choice to specific drugs. Whereas immune suppression is usually not required due to the autologous cell source, lymphodepletion may still be required to remove pre-existing immune cells reacting against the transgene, such as in patients on enzyme replacement therapy, or to eliminate autoreactive cells in autoimmune diseases.

Introducing a transgene into HSPCs and their progeny may lead to immune response toward neoantigens,²⁵⁷ especially in individuals with null mutations in the target gene or when the transgene is represented by newly engineered molecules, as host lymphocytes have not been educated to tolerate those specific peptides. Nevertheless, in the context of autologous HSPC-GT, it is expected that lymphocytes deriving from the gene-modified HSPCs undergo canonical negative selection *in vivo* for reactivity against self-antigens, including the transduced neoantigens, ensuring central tolerance. Indeed, in HSPC-GT clinical studies, immune responses to transgenes have rarely occurred,²⁵⁷ and in those cases, they were transient and did not affect clinical outcomes.²⁵⁸ Moreover, even in the event of patients carrying pre-existing antibodies to enzyme replacement therapy, such as in mucopolysaccharidosis type 1H, HSPC-GT associated with conditioning was sufficient to induce rapid disappearance of antibodies and tolerance to the transgene.¹⁵ Importantly, HSPC-GT ameliorated or resolved autoimmune manifestations of disease in the case of WAS^{12,13} even with partial engraftment of gene-corrected cells.

Non-genotoxic conditioning based on monoclonal antibodies directed against cell surface antigens expressed by all blood cells, such as CD45,^{26,97} or by HSPCs, such as CD117,^{25,259,260} may become an alternative to chemotherapy to deplete resident stem cells and have indeed demonstrated efficacy in different preclinical models.²⁶¹ Beside sparing non-hematopoietic tissues, their non-genotoxic mode of action would also alleviate concerns for muta-

tion accrual in residual HSCs surviving conditioning. Indeed, exposure to conventional conditioning regimens has been proposed to contribute to the development of some hematopoietic malignancies from pre-existing resident HSCs in SCD HSC GT trials and in mixed chimeric SCD allotransplanted patients.^{253,262} Anti-CD117 (JSP191) monoclonal antibody is currently exploited in HSCT trials, alone or in combination with chemotherapies, as a conditioning regimen in patients affected by SCID (NCT02963064), Fanconi anemia (NCT04784052), and AML or MDS (NCT04429191), respectively. Early results from an SCID trial showed that 6 out of 12 patients reached >3% donor blood granulocytes at >24 weeks post-HSCT, resulting in clinical improvement including reduced immunoglobulin dependence and antibody responses to vaccines.²⁶³ No treatment-related adverse events were reported. Monoclonal antibodies coupled with toxins or radioisotopes, combining antibody specificity with the toxicity of chemo- and radiotherapies, are under investigation in the clinic²⁶⁴ (NCT05223699). These antibody-drug conjugates showed efficient depletion of murine and human HSCs in wild-type and hematochimeric mice, respectively, as stand-alone treatments, establishing long-term stable donor chimerism with reduced toxicity as compared to classical radiotherapy.^{26,51,261} However, emergent severe toxicity has halted clinical development of one of the above-mentioned antibody-drug conjugates, raising concerns about the overall safety of administering powerful toxins, albeit coupled to a targeting molecule, to humans (<https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-voluntarily-pauses-mgta-117-phase-12-dose>).

The egress of resident HSPCs from the BM during drug-induced mobilization might generate a window of opportunity for engraftment of gene-corrected cells and has been exploited in preclinical models of conditioning regimens.²⁶⁵ Transient overexpression of CXCR4 in transplanted gene-edited HSPCs provided an engraftment advantage to infused cells, promoting efficient HSPC exchange in BM niches and stable long-term chimerism in mice.^{265–267}

HSPC-GT might gain significant benefit from alternative conditioning regimens, representing a unique clinical context in which new conditioning strategies can be tested and successfully developed, given the autologous source of the infused cell product and that a mixed chimerism might be sufficient for therapeutic benefit in many diseases amenable to GT.

CONCLUSIONS AND FUTURE PERSPECTIVES

Nearly thirty years of research and development of gene transfer vectors have provided the groundwork for successful clinical development and consolidation of HSPC-GT for a growing number of inherited hematological and metabolic diseases. The recent advent of GE bears the promise of even more precise and potentially safer genetic engineering. These advances are the outcome of a multidisciplinary cross-fertilization process from different basic and clinical research areas, including stem cell biology, biochemistry, omics sciences, bioinformatics, and hematology. New concepts and technologies are looming on the horizon with the potential to empower the design of next-generation HSPC-GT, such as nanotechnologies for stealth and targeted delivery,²⁶⁸ RNA-based instruction of gain-of-function

Table 1. Choosing the proper tool: summary of main therapeutic modalities, upsides and downsides, constraints, and current stage of development for HSPC-GT

Platform	Therapeutic modalities	Upsides	Downsides	Constraints	Stage of development
γ -Retroviral vectors	Gene addition for: <ul style="list-style-type: none"> • Gene replacement • Instructing new function • Inhibiting endogenous gene expression by micro/shRNA 	Long-established manufacturing and clinical use	<ul style="list-style-type: none"> • Insertional genotoxicity aggravated by strong enhancers in vector LTRs • Expression by reconstituted promoter in the vector may not reproduce physiological regulation 	Inefficient in long-term HSCs Semi-random integration profile Expression from viral LTRs	Several past clinical trials/market approvals for one product
SIN lentiviral vectors	•	<ul style="list-style-type: none"> • Highly efficient gene transfer (also in long-term HSCs) • Robust expression at most ISs • Solid clinical track record with long-term safety and efficacy 	<ul style="list-style-type: none"> • Residual insertional genotoxicity alleviated by SIN LTRs and promoter choice • Expression by reconstituted promoter in the vector may not reproduce physiological regulation 	Semi-random integration profile	Several past and current clinical trials/market approvals of a growing number of products
Designer nucleases	<ul style="list-style-type: none"> • Disruption of coding or regulatory sequences (also multiplex) • Suppression of dominant mutations by allele-specific knock-out • Correction of mutant gene Targeted integration of: <ul style="list-style-type: none"> • “One-size-fit-all” corrective cDNA • Expression cassette to safe harbor 	<ul style="list-style-type: none"> • Site-specific activity • Highly efficient disruption (up to biallelic) • Site-specific activity • Compatible with long-range edits • Preserves physiological regulation of the target gene 	<ul style="list-style-type: none"> • Adverse effects of DNA DSBs on long-term HSCs (p53 response) • gRNA-dependent off-target activity • Large genomic rearrangements at the target site(s) • Requires delivery of non-viral/ viral DNA templates for HDR (AAV6, IDLV, and ssDNA) • Adverse effects of DNA DSBs and DNA templates on long-term HSCs (p53 response) • gRNA-dependent off-target activity • Large genomic rearrangements at the target site(s) 	<ul style="list-style-type: none"> • Heterogeneous repair outcomes • Influence of interindividual genetic variability on the off-target profile • <i>Immunogenicity of the editor</i> • Requires HSPC cycling • Low efficiency of gene correction in HSCs • Heterogeneous repair outcomes • Influence of interindividual genetic variability on the gRNA off-target profile • <i>Immunogenicity of the editor</i> 	Early-stage clinical trials
Base editors	<ul style="list-style-type: none"> • Disruption of coding or regulatory sequence • Correction of point mutation (including dominant ones) • Installment of single nucleotide variants (SNVs) providing novel function • Multiplex editing 	<ul style="list-style-type: none"> • Site-specific activity • Low DNA DSB burden • Highly efficient (particularly adenine base editors) 	<ul style="list-style-type: none"> • Bystander editing and residual DSB generation at target site(s) • Residual gRNA-dependent off-target activity and large genomic rearrangements • <i>gRNA-independent off-target activity on DNA/RNA (deaminase)</i> 	<ul style="list-style-type: none"> • Limited to single nucleotide transitions • Mutation-specific gRNA must be designed for gene correction • <i>Influence of interindividual genetic variability on the off-target profile?</i> • <i>Immunogenicity of the editor?</i> 	Close to clinical trial (NCT05456880)

(Continued on next page)

Table 1. Continued

Platform	Therapeutic modalities	Upsides	Downsides	Constraints	Stage of development
Prime editors	<ul style="list-style-type: none"> Disruption of coding or regulatory sequence Correction of point mutations (including dominant ones) Installation of small sequence variants providing novel function <i>Multiplex editing</i> 	<ul style="list-style-type: none"> Site-specific activity Low DNA DSB burden Enable all types of nucleotide changes and mostly short-range insertions/deletions 	<ul style="list-style-type: none"> gRNA scaffold incorporation and residual DSB generation at the target site(s) Residual gRNA-dependent off-target activity and large genomic rearrangements <i>gRNA-independent off-target activity on DNA/RNA (reverse transcriptase)?</i> 	<ul style="list-style-type: none"> Suboptimal efficiency Complexity of emerging multi-component variants enabling long-range edits Mutation-specific gRNA must be designed for gene correction <i>Influence of interindividual genetic variability on the off-target profile?</i> <i>Immunogenicity of the editor?</i> 	R&D stage
Epigenetic editors	<ul style="list-style-type: none"> Gene knockdown by heritable silencing Heritable gene (over) expression <i>Multiplex editing</i> 	<ul style="list-style-type: none"> Site-specific activity Do not require DNA DSBs or SSBs 	<ul style="list-style-type: none"> <i>gRNA-independent off-target activity (e.g., methyl transferase)?</i> 	<ul style="list-style-type: none"> <i>Long-term stability of the epigenetic change?</i> 	R&D stage

Italic descriptions with or without question marks mean that these concepts have not been shown yet in general or in human HSPCs, respectively.

and chemotherapy-free HSCT,²⁶⁵ three-dimensional cell culture and bioprinting,^{204,269} *ex vivo* expanded and pluripotent stem-cell-derived HSCs,¹⁹⁹ artificial intelligence,^{270–272} and prospectively groundbreaking single-cell omics.²⁷³

Long-term molecular follow-ups in a growing number of patients and diseases will establish at clonal level the safety and resilience of hematopoietic grafts established with LV-engineered cells and open the way to broader applications to less severe as well as acquired diseases such as cancer and neuroinflammatory/degenerative diseases, exploiting HSPC engineering for tissue-targeted delivery of biotherapeutics by their progeny.

The expanding toolbox of GE tools will provide new opportunities for designing safer and innovative gene correction strategies and capturing emerging biological knowledge on HSC biology and regulation to serve the purpose of more sophisticated and powerful engineering. The concerns raised for potentially harmful cellular responses and adverse editing outcomes are forcing iterative rounds of deeper platform assessment and further engineering. Next-generation GE tools may avoid generation of any DNA break or sequence mutation, for instance by stably shutting down gene expression by epigenome editing^{79,80} or by limiting exposure to free DNA ends by transposases or engineered site-specific recombinases.^{92,274} Given the expanding toolbox for genetic engineering, the choice should be based on the fit of each tool to the intended therapeutic strategy, maximizing the predicted safety and efficacy.²⁷⁵ In Table 1, we summarize for each major family of genetic engineering tools the main therapeutic modalities, upsides and downsides, constraints, and current stage of development.

The development of more efficacious and/or predictably safer HSPC-GT products such as those offered by GE must be stringently validated by long-term clinical monitoring of treated patients and thorough assessment of the occurrence and consequences of unwanted repair outcomes upon GE. While the first HSPC GE clinical trials conducted so far have reported excellent therapeutic benefits and no evidence of cell transformation,⁶⁴ it will be important to learn about the hematopoietic graft clonality, off-target editing, and occurrence/persistence of genomic rearrangements. This information will be extremely valuable to accrue knowledge on the actual risks and limitations of HSPC GE in “real life” scenarios, helping to focus development of improved or novel platforms.

Genetic engineering of human HSPCs *in vivo*, rather than *ex vivo*, may represent the ultimate goal of HSPC-GT because it does not require cell harvesting, nor does it expose them to the potential adverse effects of *ex vivo* manipulation, and it might bypass the conditioning requirement. Furthermore, it would reduce the treatment complexity and costs, potentially widely broadening GT access. *In vivo* HSPC-GT, however, is not an easy task, notwithstanding early preclinical proof-of-concepts in mice and NHPs,^{276–278} and faces the intrinsic safety challenges related to biodistribution. Reaching a sufficient proportion of resident HSCs to establish a therapeutically effective chimerism with modified cells might be difficult, at least without coupling gene correction to a selection strategy. Bystander modification of off-target cell types inside and outside the BM might increase the probability of generating cells bearing genotoxic hits and trigger adverse reactions such as immune

sensitization to the editing machinery and transgene product. Moreover, *in vivo* HSPC-GT intrinsically bypasses the release specifications of *ex vivo* GT, which are performed on modified cells rather than on the manipulation machinery, thus greatly hampering characterization of the engineered cell product and investigation of potential detrimental consequences. Whenever applicable, *in vivo* HSPC-GT is also expected to be benchmarked against the competing *ex vivo* approach, which is supported by an ever-growing successful track record and the nearly half century of HSCT experience.

Overall, HSPC-GT may qualify as the next transforming medical approach born out of growing knowledge of HSC biology after the successful clinical development of HSCT.

ACKNOWLEDGMENTS

Work in the labs of R.D.M., A.K.R., E.M., G.F., A. Aiuti, and L.N. is supported by grants from Fondazione Telethon, the EU Horizon 2020 Program (UPGRADE to L.N. and X-PAND to R.D.M. and L.N.), the Italian Ministry of Health (GR-2019-12369499 to S.S., GR-2018-12366006 to A.K.R. and E-Rare-3 to L.N.), the Italian Ministry of University and Research (PRIN2017 to L.N.), the European Hematology Association (to S.F., A. Aprile, and R.D.M.), the New York Stem Cell Foundation (to R.D.M.), the European Research Council (ReviveSTEM to R.D.M. and ImmunoStem to A.K.R.), the Lady Tata Memorial Trust (to A.C.), the American Society of Hematology (to A. Aprile), the Louis-Jeantet Foundation through the Jeantet-Collen Prize for Translational Medicine 2019 (to L.N.), and the Else Kröner Fresenius Foundation through the Kröner-Fresenius Prize for Medical Research 2020 (to A. Aiuti). E.V. contributed to this Review as partial fulfillment of her Ph.D. A.C. is an EHA and ASH-TRTH early career hematological scientist. R.D.M. is a New York Stem Cell Foundation Robertson Investigator.

AUTHOR CONTRIBUTIONS

All authors contributed to writing this Review. S.F. and L.N. coordinated the work and integrated all contributions. The other authors are listed in order of seniority in the field.

DECLARATION OF INTERESTS

L.N. is an inventor on patents on LV technology and gene editing filed by the Salk Institute, Cell Genesys, Telethon Foundation, and/or San Raffaele Scientific Institute. S.F., A.C., R.D.M., and A.K.R. are inventors of patents on gene editing, and E.M. is an inventor of patent on clonal tracking, owned and managed by the San Raffaele Scientific Institute and Telethon Foundation. L.N. is a founder, equity owner, consultant, and member of the scientific advisory board of Genenta Science, a biotechnology company aiming at developing cancer gene therapy by tumor-infiltrating monocytes; GeneSpire, a biotechnology startup developing LV-based liver gene transfer and hematopoietic cell gene editing; and Epsilon Bio/Chroma Medicine, a company developing epigenetic editing. A. Aiuti is a PI of clinical trials sponsored by Orchard Therapeutics, which licensed several gene therapy products originally developed at SR-Tiget. A. Aiuti is a member of the EU Committee for Advanced Therapies (CAT), and his views are personal and may not be understood or quoted as being made on behalf of the European Medicines Agency (EMA). All other authors declare no competing interests.

REFERENCES

- Ferrari, G., Thrasher, A.J., and Aiuti, A. (2021). Gene therapy using haematopoietic stem and progenitor cells. *Nat. Rev. Genet.* 22 (22), 216–234. <https://doi.org/10.1038/s41576-020-00298-5>.
- Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. *Science*. <https://doi.org/10.1126/science.1070104>.
- Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science* 288, 669–672. <https://doi.org/10.1126/science.288.5466.669>.
- Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., de Villartay, J.-P., Thrasher, A.J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by *ex vivo* gene therapy. *N. Engl. J. Med.* 346, 1185–1193. <https://doi.org/10.1056/NEJMoa012616>.
- Gaspar, H.B., Parsley, K.L., Howe, S., King, D., Gilmour, K.C., Sinclair, J., Brouns, G., Schmidt, M., Von Kalle, C., Barington, T., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. *Barington, T. Lancet* 364, 2181–2187. [https://doi.org/10.1016/S0140-6736\(04\)17590-9](https://doi.org/10.1016/S0140-6736(04)17590-9).
- Aiuti, A., Roncarolo, M.G., and Naldini, L. (2017). Gene therapy for ADA-SCID, the first marketing approval of an *ex vivo* gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. *EMBO Mol. Med.* 9, 737–740. <https://doi.org/10.15252/EMMM.201707573>.
- Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., et al. (2003). LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. *Science* 302, 415–419. <https://doi.org/10.1126/science.1088547>.
- Naldini, L., Trono, D., and Verma, I.M. (2016). Lentiviral vectors, two decades later. *Science* 353, 1101–1102. <https://doi.org/10.1126/science.aah6192>.
- Kohn, D.B., Booth, C., Shaw, K.L., Xu-Bayford, J., Garabedian, E., Trevisan, V., Carbonaro-Sarracino, D.A., Soni, K., Terrazas, D., Snell, K., et al. (2021). Autologous *Ex Vivo* Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. *N. Engl. J. Med.* 384, 2002–2013. <https://doi.org/10.1056/NEJMoa2027675>.
- Cicalese, M.P., Ferrua, F., Castagnaro, L., Rolfe, K., de Boever, E., Reinhardt, R.R., Appleby, J., Roncarolo, M.G., and Aiuti, A. (2018). Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety. *Mol. Ther.* 26, 917–931. <https://doi.org/10.1016/j.ymt.2017.12.022>.
- de Ravin, S.S., Wu, X., Moir, S., Kardava, L., Anaya-O'Brien, S., Kwatema, N., Littel, P., Theobald, N., Choi, U., Su, L., et al. (2016). Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. *Sci. Transl. Med.* 8. <https://doi.org/10.1126/scitranslmed.aad8856>.
- Magnani, A., Semeraro, M., Adam, F., Booth, C., Dupré, L., Morris, E.C., Gagnoni, A., Roudaut, C., Borgel, D., Toubert, A., et al. (2022). Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome. *Nat. Med.* 28, 71–80. <https://doi.org/10.1038/s41591-021-01641-X>.
- Ferrua, F., Cicalese, M.P., Galimberti, S., Giannelli, S., Dionisio, F., Barzaghi, F., Migliaiavacca, M., Bernardo, M.E., Calbi, V., Assanelli, A.A., et al. (2019). Lentiviral haematopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. *Lancet. Haematol.* 6, e239–e253. [https://doi.org/10.1016/S2352-3026\(19\)30021-3](https://doi.org/10.1016/S2352-3026(19)30021-3).
- Kohn, D.B., Booth, C., Kang, E.M., Pai, S.Y., Shaw, K.L., Santilli, G., Arment, M., Buckland, K.F., Choi, U., de Ravin, S.S., et al. (2020). Lentiviral gene therapy for X-linked chronic granulomatous disease. *Nat Med* 26, 200–206. <https://doi.org/10.1038/s41591-019-0735-5>.
- Gentner, B., Tucci, F., Galimberti, S., Fumagalli, F., De Pellegrin, M., Silvani, P., Camesasca, C., Pontesilli, S., Darin, S., Ciotti, F., et al. (2021). Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. *N. Engl. J. Med.* 385, 1929–1940. <https://doi.org/10.1056/NEJMoa2106596>.
- Sessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I.D., Morena, F., Calabria, A., et al. (2016). Lentiviral haematopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. *Lancet* 388, 476–487. [https://doi.org/10.1016/S0140-6736\(16\)30374-9](https://doi.org/10.1016/S0140-6736(16)30374-9).
- Bougnères, P., Hacein-Bey-Abina, S., Labik, I., Adamsbaum, C., Castaignède, C., Bellesme, C., and Schmidt, M. (2021). Long-Term

- Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. *Hum. Gene Ther.* 32, 1260–1269. <https://doi.org/10.1089/HUM.2021.053>.
18. Eichler, F., Duncan, C., Musolino, P.L., Orchard, P.J., De Oliveira, S., Thrasher, A.J., Armant, M., Dansereau, C., Lund, T.C., Miller, W.P., et al. (2017). Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. *N. Engl. J. Med.* 377, 1630–1638. <https://doi.org/10.1056/NEJMoa1700554>.
 19. Markt, S., Scaramuzza, S., Cicalese, M.P., Giglio, F., Galimberti, S., Lidonnici, M.R., Calbi, V., Assanelli, A., Bernardo, M.E., Rossi, C., et al. (2019). Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β -thalassemia. *Nat. Med.* 25, 234–241. [10.1038/s41591-018-0301-6](https://doi.org/10.1038/s41591-018-0301-6).
 20. Locatelli, F., Thompson, A.A., Kwiatkowski, J.L., Porter, J.B., Thrasher, A.J., Hongeng, S., Sauer, M.G., Thuret, I., Lal, A., Algeri, M., et al. (2022). Betibeglogene Autotemcel Gene Therapy for Non- β 0/ β 0 Genotype β -Thalassemia. *N. Engl. J. Med.* 386, 415–427. <https://doi.org/10.1056/NEJMoa2113206>.
 21. Esrick, E.B., Lehmann, L.E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M.F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021). Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. *N. Engl. J. Med.* 384, 205–215. <https://doi.org/10.1056/NEJMoa2029392>.
 22. Río, P., Navarro, S., Wang, W., Sánchez-Domínguez, R., Pujol, R.M., Segovia, J.C., Bogliolo, M., Merino, E., Wu, N., Salgado, R., et al. (2019). Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. *Nat. Med.* 25, 1396–1401. <https://doi.org/10.1038/s41591-019-0550-z>.
 23. Tucci, F., Galimberti, S., Naldini, L., Valsecchi, M.G., and Aiuti, A. (2022). A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. *Nat. Commun.* 13, 1315. <https://doi.org/10.1038/s41467-022-28762-2>.
 24. Czechowicz, A., Palchadhuri, R., Scheck, A., Hu, Y., Hoggatt, J., Saez, B., Pang, W.W., Mansour, M.K., Tate, T.A., Chan, Y.Y., et al. (2019). Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. *Nat. Commun.* 10, 617. <https://doi.org/10.1038/s41467-018-08201-x>.
 25. Kwon, H.S., Logan, A.C., Chhabra, A., Pang, W.W., Czechowicz, A., Tate, K., Le, A., Poyser, J., Hollis, R., Kelly, B.V., et al. (2019). Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. *Blood* 133, 2104–2108. <https://doi.org/10.1182/BLOOD-2018-06-853879>.
 26. Palchadhuri, R., Saez, B., Hoggatt, J., Schajnovitz, A., Sykes, D.B., Tate, T.A., Czechowicz, A., Kfoury, Y., Ruchika, F.N.U., Rossi, D.J., et al. (2016). Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. *Nat. Biotechnol.* 34 (34), 738–745. <https://doi.org/10.1038/nbt.3584>.
 27. Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. *Science* 341. <https://doi.org/10.1126/science.1233158>.
 28. Peviani, M., Das, S., Patel, J., Jno-Charles, O., Kumar, R., Zguro, A., Mathews, T.D., Cabras, P., Milazzo, R., Cavalca, E., et al. (2023). An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model. *EMBO Mol. Med.* e15968. <https://doi.org/10.15252/EMMM.202215968>.
 29. Birocchi, F., Cusimano, M., Rossari, F., Beretta, S., Rancoita, P.M.V., Ranghetti, A., Colombo, S., Costa, B., Angel, P., Sanvito, F., et al. (2022). Targeted inducible delivery of immunostimulating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models. *Sci. Transl. Med.* 14, 4106. <https://doi.org/10.1126/scitranslmed.abl4106>.
 30. Mucci, A., Antonarelli, G., Caserta, C., Vittoria, F.M., Desantis, G., Paganani, R., Greco, B., Casucci, M., Escobar, G., Passerini, L., et al. (2021). Myeloid cell-based delivery of IFN- γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses. *EMBO Mol. Med.* 13, e13598. <https://doi.org/10.15252/EMMM.202013598>.
 31. Escobar, G., Barbarossa, L., Barbiera, G., Norelli, M., Genua, M., Ranghetti, A., Plati, T., Camisa, B., Brombin, C., Cittaro, D., et al. (2018). Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens. *Nat. Commun.* 9, 2896. <https://doi.org/10.1038/s41467-018-05315-0>.
 32. Craigie, R., and Bushman, F.D. (2014). Host Factors in Retroviral Integration and the Selection of Integration Target Sites. *Microbiol. Spectr.* 2. <https://doi.org/10.1128/microbiolspec.MDNA3-0026-2014>.
 33. Hacein-Bey Abina, S., Gaspar, H.B., Blondeau, J., Caccavelli, L., Charrier, S., Buckland, K., Picard, C., Six, E., Himoudi, N., Gilmour, K., et al. (2015). Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. *JAMA* 313, 1550–1563. <https://doi.org/10.1001/JAMA.2015.3253>.
 34. Cesana, D., Calabria, A., Rudilosso, L., Gallina, P., Benedicenti, F., Spinuzzi, G., Schirolli, G., Magnani, A., Acquati, S., Fumagalli, F., et al. (2021). Retrieval of vector integration sites from cell-free DNA. *Nat. Med.* 27, 1458–1470. <https://doi.org/10.1038/s41591-021-01389-4>.
 35. Thompson, A.A., Walters, M.C., Kwiatkowski, J., Rasko, J.E.J., Ribeil, J.A., Hongeng, S., Magrin, E., Schiller, G.J., Payen, E., Semeraro, M., et al. (2018). Gene therapy in patients with transfusion-dependent β -thalassemia. *N. Engl. J. Med.* 378, 1479–1493. <https://doi.org/10.1056/NEJMoa1705342>.
 36. Six, E., Guilloux, A., Denis, A., Lecoules, A., Magnani, A., Vilette, R., Male, F., Cagnard, N., Delville, M., Magrin, E., et al. (2020). Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs. *Blood* 135, 1219–1231. <https://doi.org/10.1182/BLOOD.2019002350>.
 37. Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M.P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M.C., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with wiskott-aldrich syndrome. *Science* 341. <https://doi.org/10.1126/science.1233151>.
 38. Scala, S., Basso-Ricci, L., Dionisio, F., Pellin, D., Giannelli, S., Salerio, F.A., Leonardelli, L., Cicalese, M.P., Ferrua, F., Aiuti, A., and Biasco, L. (2018). Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans. *Nat. Med.* 24, 1683–1690. <https://doi.org/10.1038/s41591-018-0195-3>.
 39. Scala, S., and Aiuti, A. (2019). In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions. *Blood Adv.* 3, 1916–1924. <https://doi.org/10.1182/BLOODADVANCES.2019000039>.
 40. Bowman, R.L., Busque, L., and Levine, R.L. (2018). Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. *Cell Stem Cell* 22, 157–170. <https://doi.org/10.1016/j.stem.2018.01.011>.
 41. Kebriaei, P., Izsvák, Z., Narayanavari, S.A., Singh, H., and Ivics, Z. (2017). Gene Therapy with the Sleeping Beauty Transposon System. *Trends Genet.* 33, 852–870. <https://doi.org/10.1016/j.tig.2017.08.008>.
 42. Tipanee, J., Chai, Y.C., VandenDriessche, T., and Chuah, M.K. (2017). Preclinical and clinical advances in transposon-based gene therapy. *Chuah, M.K. Biosci. Rep.* 37. <https://doi.org/10.1042/BSR20160614>.
 43. Moretti, A., Ponzo, M., Nicolette, C.A., Tcherepanova, I.Y., Biondi, A., and Magnani, C.F. (2022). The Past, Present, and Future of Non-Viral CAR T Cells. *Front. Immunol.* 13, 867013. <https://doi.org/10.3389/fimmu.2022.867013>.
 44. Doudna, J.A. (2020). The promise and challenge of therapeutic genome editing. *Nature* 578, 229–236. <https://doi.org/10.1038/s41586-020-1978-5>.
 45. Scully, R., Panday, A., Elango, R., and Willis, N.A. (2019). DNA double-strand break repair-pathway choice in somatic mammalian cells. *Nat. Rev. Mol. Cell Biol.* 20 (20), 698–714. <https://doi.org/10.1038/s41580-019-0152-0>.
 46. de Ravin, S.S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., et al. (2017). CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. *Sci. Transl. Med.* 9, eaah3480. <https://doi.org/10.1126/scitranslmed.aah3480>.

47. Shy, B.R., Vykunta, V.S., Ha, A., Talbot, A., Roth, T.L., Nguyen, D.N., Pfeifer, W.G., Chen, Y.Y., Blaeschke, F., Shifrut, E., et al. (2022). High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. *Nat. Biotechnol.* 2022, 1–11. <https://doi.org/10.1038/s41587-022-01418-8>.
48. Wang, J., Exline, C.M., Declercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W.L., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. *Nat. Biotechnol.* 33, 1256–1263. <https://doi.org/10.1038/nbt.3408>.
49. Genovese, P., Schirotti, G., Escobar, G., Tomaso, T.D., Firrito, C., Calabria, A., Moi, D., Mazzeri, R., Bonini, C., Holmes, M.C., et al. (2014). Targeted genome editing in human repopulating haematopoietic stem cells. *Nature* 510, 235–240. <https://doi.org/10.1038/nature13420>.
50. Ferrari, S., Jacob, A., Cesana, D., Laugel, M., Beretta, S., Varesi, A., Unali, G., Conti, A., Canarutto, D., Albano, L., et al. (2022). Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. *Cell Stem Cell* 29, 1428–1444. <https://doi.org/10.1016/j.stem.2022.09.001>.
51. Schirotti, G., Conti, A., Ferrari, S., della Volpe, L., Jacob, A., Albano, L., Beretta, S., Calabria, A., Vavassori, V., Gasparini, P., et al. (2019). Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response. *Cell Stem Cell* 24, 551–565. <https://doi.org/10.1016/j.stem.2019.02.019>.
52. Patabhi, S., Lotti, S.N., Berger, M.P., Singh, S., Lux, C.T., Jacoby, K., Lee, C., Negre, O., Scharenberg, A.M., and Rawlings, D.J. (2019). Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods. *Mol. Ther. Nucleic Acids* 17, 277–288. <https://doi.org/10.1016/j.omtn.2019.05.025>.
53. Romero, Z., Lomova, A., Said, S., Miggelbrink, A., Kuo, C.Y., Campo-Fernandez, B., Hoban, M.D., Masiuk, K.E., Clark, D.N., Long, J., et al. (2019). Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates. *Mol. Ther.* 27, 1389–1406. <https://doi.org/10.1016/j.jymthe.2019.05.014>.
54. Ferrari, S., Jacob, A., Beretta, S., Unali, G., Albano, L., Vavassori, V., Citaro, D., Lazarevic, D., Brombin, C., Cugnata, F., et al. (2020). Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. *Nat. Biotechnol.* 38, 1298–1308. <https://doi.org/10.1038/s41587-020-0551-y>.
55. Wu, Y., Zeng, J., Roscoe, B.P., Liu, P., Yao, Q., Lazzarotto, C.R., Clement, K., Cole, M.A., Luk, K., Baricordi, C., et al. (2019). Highly efficient therapeutic gene editing of human hematopoietic stem cells. *Nat. Med.* 25, 776–783. <https://doi.org/10.1038/s41591-019-0401-y>.
56. Demirci, S., Zeng, J., Wu, Y., Uchida, N., Shen, A.H., Pellin, D., Gamer, J., Yapundich, M., Drysdale, C., Bonanno, J., et al. (2020). BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity. *J. Clin. Invest.* 130, 6677–6687. <https://doi.org/10.1172/JCI140189>.
57. Charlesworth, C.T., Camarena, J., Cromer, M.K., Vaidyanathan, S., Bak, R.O., Carte, J.M., Potter, J., Dever, D.P., and Porteus, M.H. (2018). Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. *Mol. Ther. Nucleic Acids* 12, 89–104. <https://doi.org/10.1016/j.omtn.2018.04.017>.
58. Lattanzi, A., Camarena, J., Lahiri, P., Segal, H., Srifa, W., Vakulskas, C.A., Frock, R.L., Kenrick, J., Lee, C., Talbot, N., et al. (2021). Development of β -globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. *Sci. Transl. Med.* 13, eabf2444. <https://doi.org/10.1126/scitranslmed.abf2444>.
59. Lomova, A., Clark, D.N., Campo-Fernandez, B., Flores-Bjurstrom, C., Kaufman, M.L., Fitz-Gibbon, S., Wang, X., Miyahira, E.Y., Brown, D., DeWitt, M.A., et al. (2019). Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA Repair. *Stem Cell* 37, 284–294. <https://doi.org/10.1002/stem.2935>.
60. Shin, J.J., Schröder, M.S., Caiado, F., Wyman, S.K., Bray, N.L., Bordi, M., Dewitt, M.A., Vu, J.T., Kim, W.T., Hockemeyer, D., et al. (2020). Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells. *Cell Rep.* 32, 108093. <https://doi.org/10.1016/j.celrep.2020.108093>.
61. Canny, M.D., Moatti, N., Wan, L.C.K., Fradet-Turcotte, A., Krasner, D., Mateos-Gomez, P.A., Zimmermann, M., Orthwein, A., Juang, Y.C., Zhang, W., et al. (2018). Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR–Cas9 genome-editing efficiency. *Nat. Biotechnol.* 36 (36), 95–102. <https://doi.org/10.1038/nbt.4021>.
62. Rai, R., Romito, M., Rivers, E., Turchiano, G., Blattner, G., Vetharoy, W., Ladon, D., Andrieux, G., Zhang, F., Zincola, M., et al. (2020). Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome. *Nat. Commun.* 11, 4034. <https://doi.org/10.1038/s41467-020-17626-2>.
63. Nguyen, D.N., Roth, T.L., Li, P.J., Chen, P.A., Apathy, R., Mamedov, M.R., Vo, L.T., Tobin, V.R., Goodman, D., Shifrut, E., et al. (2020). Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. *Nat. Biotechnol.* 38, 44–49. <https://doi.org/10.1038/s41587-019-0325-6>.
64. Frangoul, H., Altschuler, D., Cappellini, M.D., Chen, Y.-S., Domm, J., Eustace, B.K., Foell, J., de la Fuente, J., Handgretinger, R., et al. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β -Thalassemia. *N. Engl. J. Med.* 384, 252–260. <https://doi.org/10.1056/NEJMoa2031054>.
65. Anzalone, A.V., Koblan, L.W., and Liu, D.R. (2020). Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. *Nat. Biotechnol.* 38 (38), 824–844. <https://doi.org/10.1038/s41587-020-0561-9>.
66. Chen, P.J., Hussmann, J.A., Yan, J., Knipping, F., Ravisankar, P., Chen, P.F., Chen, C., Nelson, J.W., Newby, G.A., Sahin, M., et al. (2021). Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. *Cell* 184, 5635–5652. <https://doi.org/10.1016/j.cell.2021.09.018>.
67. Ferreira da Silva, J., Oliveira, G.P., Arasa-Verge, E.A., Kagiou, C., Moreton, A., Timelthaler, G., Jiricny, J., and Loizou, J.I. (2022). Prime editing efficiency and fidelity are enhanced in the absence of mismatch repair. *Nat. Commun.* 13, 760. <https://doi.org/10.1038/s41467-022-28442-1>.
68. Koblan, L.W., Doman, J.L., Wilson, C., Levy, J.M., Tay, T., Newby, G.A., Maianti, J.P., Raguram, A., and Liu, D.R. (2018). Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. *Nat. Biotechnol.* 36, 843–846. <https://doi.org/10.1038/nbt.4172>.
69. Yarnall, M.T.N., Ioannidi, E.I., Schmitt-Ulms, C., Krajcski, R.N., Lim, J., Villiger, L., Zhou, W., Jiang, K., Garushyants, S.K., Roberts, N., et al. (2022). Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. *Nat. Biotechnol.* 41, 500–512. <https://doi.org/10.1038/s41587-022-01527-4>.
70. Anzalone, A.V., Gao, X.D., Podracky, C.J., Nelson, A.T., Koblan, L.W., Raguram, A., Levy, J.M., Mercer, J.A.M., and Liu, D.R. (2022). Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. *Nat. Biotechnol.* 40, 731–740. <https://doi.org/10.1038/s41587-021-01133-w>.
71. Jiang, T., Zhang, X.O., Weng, Z., and Xue, W. (2022). Deletion and replacement of long genomic sequences using prime editing. *Nat. Biotechnol.* 40, 227–234. <https://doi.org/10.1038/s41587-021-01026-y>.
72. Wang, J., He, Z., Wang, G., Zhang, R., Duan, J., Gao, P., Lei, X., Qiu, H., Zhang, C., Zhang, Y., and Yin, H. (2022). Efficient targeted insertion of large DNA fragments without DNA donors. *Nat. Methods* 19, 331–340. <https://doi.org/10.1038/s41592-022-01399-1>.
73. Newby, G.A., Yen, J.S., Woodard, K.J., Mayuranathan, T., Lazzarotto, C.R., Li, Y., Sheppard-Tillman, H., Porter, S.N., Yao, Y., Mayberry, K., et al. (2021). Base editing of haematopoietic stem cells rescues sickle cell disease in mice. *Nature* 595, 295–302. <https://doi.org/10.1038/s41586-021-03609-w>.
74. Siegener, S.M., Ugalde, L., Clemens, A., Garcia-Garcia, L., Bueren, J.A., Rio, P., Karasu, M.E., and Corn, J.E. (2022). Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells. *Nat. Commun.* 13, 6900. <https://doi.org/10.1038/S41467-022-34479-Z>.
75. Hardouin, G., Antoniou, P., Martinucci, P., Felix, T., Manceau, S., Joseph, L., Masson, C., Scaramuzza, S., Ferrari, G., Cavazzana, M., et al. (2022). Adenine base editor-mediated correction of the common and severe IVS1–110 (G>A) β -thalassaemia mutation. *Blood* 141, 1169–1179. <https://doi.org/10.1182/BLOOD.2022016629>.

76. Antoniou, P., Hardouin, G., Martinucci, P., Frati, G., Felix, T., Chalumeau, A., Fontana, L., Martin, J., Masson, C., Brusson, M., et al. (2022). Base-editing-mediated dissection of a γ -globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression. *Nat. Commun.* 13, 6618. <https://doi.org/10.1038/S41467-022-34493-1>.
77. Zeng, J., Wu, Y., Ren, C., Bonanno, J., Shen, A.H., Shea, D., Gehrke, J.M., Clement, K., Luk, K., Yao, Q., et al. (2020). Therapeutic base editing of human hematopoietic stem cells. *Nat. Med.* 26, 535–541. <https://doi.org/10.1038/s41591-020-0790-y>.
78. Li, C., Georgakopoulou, A., Newby, G.A., Chen, P.J., Everette, K.A., Paschoudi, K., Vlachaki, E., Gil, S., Anderson, A.K., Koob, T., et al. (2023). In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model. *Blood*. <https://doi.org/10.1182/blood.2022018252>.
79. Amabile, A., Migliara, A., Capasso, P., Biffi, M., Cittaro, D., Naldini, L., and Lombardo, A. (2016). Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. *Cell* 167, 219–232. <https://doi.org/10.1016/j.cell.2016.09.006>.
80. Nuñez, J.K., Chen, J., Pommier, G.C., Cogan, J.Z., Replogle, J.M., Adriaens, C., Ramadoss, G.N., Shi, Q., Hung, K.L., Samelson, A.J., et al. (2021). Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. *Cell* 184, 2503–2519. <https://doi.org/10.1016/J.CELL.2021.03.025>.
81. Casini, A., Olivieri, M., Petris, G., Montagna, C., Reginato, G., Maule, G., Lorenzin, F., Prandi, D., Romanel, A., Demichelis, F., et al. (2018). A highly specific SpCas9 variant is identified by in vivo screening in yeast. *Nat. Biotechnol.* 36, 265–271. <https://doi.org/10.1038/nbt.4066>.
82. Walton, R.T., Christie, K.A., Whittaker, M.N., and Kleinstiver, B.P. (2020). Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. *Science* 368, 290–296. <https://doi.org/10.1126/science.aba8853>.
83. Kleinstiver, B.P., Prew, M.S., Tsai, S.Q., Topkar V.V., Yeh J.R.J., et al., Nguyen N.T., Zheng, Z., Gonzales, A.P.W., Li, Z., et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. *Nature* 523, 481–485. <https://doi.org/10.1038/nature14592>.
84. Hu, J.H., Miller, S.M., Geurts, M.H., Tang, W., Chen, L., Sun, N., Zeina, C.M., Gao, X., Rees, H.A., Lin, Z., and Liu, D.R. (2018). Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature* 556, 57–63. <https://doi.org/10.1038/NATURE26155>.
85. Vakulskas, C.A., Dever, D.P., Rettig, G.R., Turk, R., Jacobi, A.M., Collingwood, M.A., Bode, N.M., McNeill, M.S., Yan, S., Camarena, J., et al. (2018). A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. *Nat. Med.* 24, 1216–1224. <https://doi.org/10.1038/s41591-018-0137-0>.
86. Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., and Joung, J.K. (2016). High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* 529, 490–495. <https://doi.org/10.1038/nature16526>.
87. Nishimasu, H., Shi, X., Ishiguro, S., Gao, L., Hirano, S., Okazaki, S., Noda, T., Abudayyeh, O.O., Gootenberg, J.S., Mori, H., et al. (2018). Engineered CRISPR-Cas9 nuclease with expanded targeting space. *Science* 361, 1259–1262. <https://doi.org/10.1126/SCIENCE.AAS9129>.
88. Müller, M., Lee, C.M., Gasiunas, G., Davis, T.H., Cradick, T.J., Siksnys, V., Bao, G., Cathomen, T., and Musolino, C. (2016). Streptococcus thermophilus CRISPR-Cas9 systems enable specific editing of the human genome. *Mol. Ther.* 24, 636–644. <https://doi.org/10.1038/mt.2015.218>.
89. Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., Kriz, A.J., Zetsche, B., Shalem, O., Wu, X., Makarova, K.S., et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. *Nature* 520, 186–191. <https://doi.org/10.1038/NATURE14299>.
90. Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O., Slaymaker, I.M., Makarova, K.S., Essletzbichler, P., Volz, S.E., Joung, J., van der Oost, J., Regev, A., et al. (2015). Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. *Cell* 163, 759–771. <https://doi.org/10.1016/j.cell.2015.09.038>.
91. Strecker, J., Ladha, A., Gardner, Z., Schmid-Burgk, J.L., Makarova, K.S., Koonin, E.V., and Zhang, F. (2019). RNA-guided DNA insertion with CRISPR-associated transposases. *v.*, and Zhang, F. *Science* 365, 48–53. <https://doi.org/10.1126/SCIENCE.AAX9181>.
92. Karvelis, T., Druteika, G., Bigelyte, G., Budre, K., Zedaveinyte, R., Silanskas, A., Kazlauskas, D., Venclovas, C., and Siksnys, V. (2021). Transposon-associated TnpB is a programmable RNA-guided DNA endonuclease. *Nature* 599, 692–696. <https://doi.org/10.1038/s41586-021-04058-1>.
93. Pallarès-Masmitjà, M., Ivancić, D., Mir-Pedrol, J., Jaraba-Wallace, J., Tagliani, T., Oliva, B., Rahmeh, A., Sánchez-Mejías, A., and Güell, M. (2021). Find and cut-and-transfer (FICAT) mammalian genome engineering. *Nat. Commun.* 12, 7071–7079. <https://doi.org/10.1038/s41467-021-27183-x>.
94. Tou, C.J., Orr, B., and Kleinstiver, B.P. (2023). Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases. *Nat. Biotechnol.* <https://doi.org/10.1038/s41587-022-01574-x>.
95. Hendel, A., Bak, R.O., Clark, J.T., Kennedy, A.B., Ryan, D.E., Roy, S., Steinfeld, I., Lunstad, B.D., Kaiser, R.J., Wilkens, A.B., et al. (2015). Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nat. Biotechnol.* 33, 985–989. <https://doi.org/10.1038/nbt.3290>.
96. Dever, D.P., Bak, R.O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C.E., Pavel-Dinu, M., Saxena, N., Wilkens, A.B., Mantri, S., et al. (2016). CRISPR/Cas9 β -globin gene targeting in human haematopoietic stem cells. *Nature* 539, 384–389. <https://doi.org/10.1038/nature20134>.
97. Schirotti, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M.C., Sanvito, F., Gennery, A.R., et al. (2017). Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. *Sci. Transl. Med.* 9, eaan0820. <https://doi.org/10.1126/scitranslmed.aan0820>.
98. El-Kharrag, R., Berckmueller, K.E., Madhu, R., Cui, M., Campoy, G., Mack, H.M., Wolf, C.B., Perez, A.M., Humbert, O., Kiem, H.P., and Radtke, S. (2022). Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells. *Mol. Ther.* 30, 2186–2198. <https://doi.org/10.1016/J.YMTHE.2022.02.026>.
99. Mitchell, E., Spencer Chapman, M., Williams, N., Dawson, K.J., Mende, N., Calderbank, E.F., Jung, H., Mitchell, T., Coorens, T.H.H., Spencer, D.H., et al. (2022). Clonal dynamics of haematopoiesis across the human lifespan. *Nature* 606, 343–350. <https://doi.org/10.1038/s41586-022-04786-y>.
100. Lee-Six, H., Øbro, N.F., Shepherd, M.S., Grossmann, S., Dawson, K., Belmonte, M., Osborne, R.J., Huntly, B.J.P., Martincorena, I., Anderson, E., et al. (2018). Population dynamics of normal human blood inferred from somatic mutations. *Nature* 561, 473–478. <https://doi.org/10.1038/S41586-018-0497-0>.
101. Cull, A.H., Spencer Chapman, M., Ciuculescu, M., Mitchell, E., Armant, M., Boyd, G., Esrick, E.B., Williams, D.A., Campbell, P.J., and Kent, D.G. (2021). Clonal Tracking By Whole Genome Sequencing Permits Comprehensive Mapping of the Genomic Landscape in Pre- and Post-Genes Therapy Sickle Cell Patients. *Blood* 138, 559. <https://doi.org/10.1182/BLOOD-2021-152262>.
102. Arumugam, P.I., Higashimoto, T., Urbinati, F., Modlich, U., Nestheide, S., Xia, P., Fox, C., Corsinotti, A., Baum, C., and Malik, P. (2009). Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. *Mol. Ther.* 17, 1929–1937. <https://doi.org/10.1038/MT.2009.183>.
103. Schwarzer, A., Talbot, S.R., Selich, A., Morgan, M., Schott, J.W., Dittrich-Breiholz, O., Bastone, A.L., Weigel, B., Ha, T.C., Dziadek, V., et al. (2021). Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning. *Mol. Ther.* 29, 3383–3397. <https://doi.org/10.1016/J.YMTHE.2021.06.017>.
104. Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knöss, S., Schambach, A., and Baum, C. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. *Blood* 108, 2545–2553. <https://doi.org/10.1182/blood-2005-08-024976>.
105. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C.C., Ranzani, M., Benedicenti, F., Sergi, L.S., Ambrosi, A., Ponzoni, M., et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse

- model of HSC gene therapy. *J. Clin. Invest.* 119, 964–975. <https://doi.org/10.1172/JCI37630>.
106. Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014). Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. *Mol. Ther.* 22, 774–785. <https://doi.org/10.1038/mt.2014.3>.
 107. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi Sergi, L., Benedicenti, F., Ambrosi, A., di Serio, C., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. *Nat. Biotechnol.* 24, 687–696. <https://doi.org/10.1038/nbt1216>.
 108. Zufferey, R., Dull, T., Mandel, R.J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono, D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. *J. Virol.* 72, 9873–9880. <https://doi.org/10.1128/JVI.72.12.9873-9880.1998>.
 109. Cesana, D., Sgualdino, J., Rudilosso, L., Merella, S., Naldini, L., and Montini, E. (2012). Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. *J. Clin. Invest.* 122, 1667–1676. <https://doi.org/10.1172/JCI62189>.
 110. Moiani, A., Paleari, Y., Sartori, D., Mezzadra, R., Miccio, A., Cattoglio, C., Cocchiarella, F., Lidonnici, M.R., Ferrari, G., and Mavilio, F. (2012). Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. *J. Clin. Invest.* 122, 1653–1666. <https://doi.org/10.1172/JCI61852>.
 111. Scholz, S.J., Fronza, R., Bartholomä, C.C., Cesana, D., Montini, E., von Kalle, C., Gil-Farina, I., and Schmidt, M. (2017). Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation. *Hum. Gene Ther.* 28, 875–885. <https://doi.org/10.1089/HUM.2017.162>.
 112. Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010). Transfusion independence and HMG2A activation after gene therapy of human β -thalassaemia. *Nature* 467, 318–322. <https://doi.org/10.1038/nature09328>.
 113. de Ravin, S.S., Liu, S., Sweeney, C.L., Brault, J., Whiting-Theobald, N., Ma, M., Liu, T., Choi, U., Lee, J., O'Brien, S.A., et al. (2022). Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMG2A in human X-linked severe combined immunodeficiency. *Nat. Commun.* 13, 3710–3715. <https://doi.org/10.1038/s41467-022-31344-x>.
 114. Servick, K. (2021). Gene therapy clinical trial halted as cancer risk surfaces. *Science*. AAAS. www.science.org/content/article/gene-therapy-clinical-trial-halted-cancer-risk-surfaces.
 115. (2022). 2022 ASGCT Annual Meeting Abstracts. *Mol. Ther.* 30, 1–592. <https://doi.org/10.1016/J.YMTHE.2022.04.017>.
 116. Liu, M., Maurano, M.T., Wang, H., Qi, H., Song, C.Z., Navas, P.A., Emery, D.W., Stamatoyannopoulos, J.A., and Stamatoyannopoulos, G. (2015). Genomic discovery of potent chromatin insulators for human gene therapy. *Nat. Biotechnol.* 33, 198–203. <https://doi.org/10.1038/NBT.3062>.
 117. di Micco, R., Krizhanovsky, V., Baker, D., and d'Adda di Fagagna, F. (2021). Cellular senescence in ageing: from mechanisms to therapeutic opportunities. *Nat. Rev. Mol. Cell Biol.* 22, 75–95. <https://doi.org/10.1038/S41580-020-00314-W>.
 118. Biavasco, R., Lettera, E., Giannetti, K., Gilioli, D., Beretta, S., Conti, A., Scala, S., Cesana, D., Gallina, P., Norelli, M., et al. (2021). Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. *Nat. Commun.* 12, 4559. <https://doi.org/10.1038/S41467-021-24876-1>.
 119. Kosicki, M., Tomberg, K., and Bradley, A. (2018). Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* 36, 899. <https://doi.org/10.1038/nbt.4192>.
 120. Hanlon, K.S., Kleinstiver, B.P., Garcia, S.P., Zaborowski, M.P., Volak, A., Spirig, S.E., Muller, A., Sousa, A.A., Tsai, S.Q., Bengtsson, N.E., et al. (2019). High levels of AAV vector integration into CRISPR-induced DNA breaks. *Nat. Commun.* 10, 4439. <https://doi.org/10.1038/s41467-019-12449-2>.
 121. Nelson, C.E., Wu, Y., Gemberling, M.P., Oliver, M.L., Waller, M.A., Bohning, J.D., Robinson-Hamm, J.N., Bulaklak, K., Castellanos Rivera, R.M., Collier, J.H., et al. (2019). Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. *Nat. Med.* 25, 427–432. <https://doi.org/10.1038/s41591-019-0344-3>.
 122. Tsai, S.Q., and Joung, J.K. (2016). Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases. *Nat. Rev. Genet.* 17, 300–312. <https://doi.org/10.1038/NRG.2016.28>.
 123. Clement, K., Hsu, J.Y., Canver, M.C., Joung, J.K., and Pinello, L. (2020). Technologies and Computational Analysis Strategies for CRISPR Applications. *Mol. Cell* 79, 11–29. <https://doi.org/10.1016/J.MOLCEL.2020.06.012>.
 124. AlJanahi, A.A., Lazzarotto, C.R., Chen, S., Shin, T.H., Cordes, S., Fan, X., Jabara, I., Zhou, Y., Young, D.J., Lee, B.C., et al. (2022). Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques. *Mol. Ther.* 30, 209–222. <https://doi.org/10.1016/J.YMTHE.2021.06.016>.
 125. Cromer, M.K., Majeti, K.R., Rettig, G.R., Murugan, K., Kurgan, G.L., Bode, N.M., Hampton, J.P., Vakulskas, C.A., Behlke, M.A., and Porteus, M.H. (2023). Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells. *Mol. Ther.* 31, 1074–1087. <https://doi.org/10.1016/J.YMTHE.2023.02.011>.
 126. Chung, C.H., Allen, A.G., Sullivan, N.T., Atkins, A., Nonnemacher, M.R., Wigdahl, B., and Dampier, W. (2020). Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR–Cas9 Cleavage Efficiency. *Mol. Ther.* 28, 19–28. <https://doi.org/10.1016/J.YMTHE.2019.10.008>.
 127. Cameron, P., Fuller, C.K., Donohoue, P.D., Jones, B.N., Thompson, M.S., Carter, M.M., Gradia, S., Vidal, B., Garner, E., Slorach, E.M., et al. (2017). Mapping the genomic landscape of CRISPR–Cas9 cleavage. *Nat. Methods* 14, 600–606. <https://doi.org/10.1038/nmeth.4284>.
 128. Petri, K., Kim, D.Y., Sasaki, K.E., Canver, M.C., Wang, X., Shah, H., Lee, H., Horng, J.E., Clement, K., Iyer, S., et al. (2021). Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects. Preprint at bioRxiv. <https://doi.org/10.1101/2021.04.05.438458>.
 129. Cancellieri, S., Zeng, J., Lin, L.Y., Tognon, M., Nguyen, M.A., Lin, J., Bombieri, N., Maitland, S.A., Ciuculescu, M.F., Katta, V., et al. (2023). Human genetic diversity alters off-target outcomes of therapeutic gene editing. *Nat. Genet.* 55, 34–43. <https://doi.org/10.1038/S41588-022-01257-Y>.
 130. Kosicki, M., Allen, F., Steward, F., Tomberg, K., Pan, Y., and Bradley, A. (2022). Cas9-induced large deletions and small indels are controlled in a convergent fashion. *Nat. Commun.* 13, 3422. <https://doi.org/10.1038/S41467-022-30480-8>.
 131. Owens, D.D.G., Caulder, A., Frontera, V., Harman, J.R., Allan, A.J., Bucacki, A., Greder, L., Codner, G.F., Hublitz, P., McHugh, P.J., et al. (2019). Microhomologies are prevalent at Cas9-induced larger deletions. *Nucleic Acids Res.* 47, 7402–7417. <https://doi.org/10.1093/NAR/GKZ459>.
 132. Adikusuma, F., Piltz, S., Corbett, M.A., Turvey, M., McColl, S.R., Helbig, K.J., Beard, M.R., Hughes, J., Pomerantz, R.T., and Thomas, P.Q. (2018). Large deletions induced by Cas9 cleavage. *Nature* 560, E8–E9. <https://doi.org/10.1038/s41586-018-0380-z>.
 133. Weisheit, I., Kroeger, J.A., Malik, R., Wefers, B., Lichtner, P., Wurst, W., Dichgans, M., and Paquet, D. (2021). Simple and reliable detection of CRISPR-induced on-target effects by qPCR and SNP genotyping. *Nat. Protoc.* 16, 1714–1739. <https://doi.org/10.1038/S41596-020-00481-2>.
 134. Park, S.H., Cao, M., Pan, Y., Davis, T.H., Saxena, L., Deshmukh, H., Fu, Y., Treangen, T., Sheehan, V.A., and Bao, G. (2022). Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR–Cas9 gene editing. *Sci Adv* 8, eabo7676. <https://doi.org/10.1126/SCIADV.ABO7676>.
 135. Nahmad, A.D., Reuveni, E., Goldschmidt, E., Tenne, T., Liberman, M., Horovitz-Fried, M., Khosravi, R., Kobo, H., Reinstein, E., Madi, A., et al. (2022). Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage. *Nat. Biotechnol.* 40, 1807–1813. <https://doi.org/10.1038/s41587-022-01377-0>.

136. Turchiano, G., Andrieux, G., Klermund, J., Blattner, G., Pennucci, V., el Gaz, M., Monaco, G., Poddar, S., Mussolino, C., Cornu, T.I., et al. (2021). Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. *Cell Stem Cell* 28, 1136–1147. <https://doi.org/10.1016/j.stem.2021.02.002>.
137. Amendola, M., Brusson, M., and Miccio, A. (2022). CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy. *Stem Cells Transl. Med.* 11, 1003–1009. <https://doi.org/10.1093/STCLM/SZAC064>.
138. Leibowitz, M.L., Papataniou, S., Doerfler, P.A., Blaine, L.J., Sun, L., Yao, Y., Zhang, C.Z., Weiss, M.J., and Pellman, D. (2021). Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing. *Nat. Genet.* 53, 895–905. <https://doi.org/10.1038/s41588-021-00838-7>.
139. Colella, P., Ronzitti, G., and Mingozzi, F. (2018). Emerging Issues in AAV-Mediated In Vivo Gene Therapy. *Mol. Ther. Methods Clin. Dev.* 8, 87–104. <https://doi.org/10.1016/j.omtm.2017.11.007>.
140. Dalwadi, D.A., Calabria, A., Tiyaonchai, A., Posey, J., Naugler, W.E., Montini, E., and Grompe, M. (2021). AAV integration in human hepatocytes. *Mol. Ther.* 29, 2898–2909. <https://doi.org/10.1016/j.ymthe.2021.08.031>.
141. Nguyen, G.N., Everett, J.K., Kafle, S., Roche, A.M., Raymond, H.E., Leiby, J., Wood, C., Assenmacher, C.A., Merricks, E.P., Long, C.T., et al. (2021). A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. *Bio-technol.* 39 (39), 47–55. <https://doi.org/10.1038/s41587-020-0741-7>.
142. Nakai, H., Montini, E., Fuess, S., Storm, T.A., Grompe, M., and Kay, M.A. (2003). AAV serotype 2 vectors preferentially integrate into active genes in mice. *Nat. Genet.* 34, 297–302. <https://doi.org/10.1038/ng1179>.
143. Chandler, R.J., Sands, M.S., and Venditti, C.P. (2017). Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models. *Hum. Gene Ther.* 28, 314–322. <https://doi.org/10.1089/HUM.2017.009>.
144. di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garré, M., Nuciforo, P.G., Bensimon, A., et al. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* 444, 638–642. <https://doi.org/10.1038/nature05327>.
145. Jeong, Y.K., Song, B., and Bae, S. (2020). Current Status and Challenges of DNA Base Editing Tools. *Mol. Ther.* 28, 1938–1952. <https://doi.org/10.1016/j.ymthe.2020.07.021>.
146. Zuo, E., Sun, Y., Wei, W., Yuan, T., Ying, W., Sun, H., Yuan, L., Steinmetz, L.M., Li, Y., and Yang, H. (2019). Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. *Science* 364, 289–292. <https://doi.org/10.1126/SCIENCE.AAV9973>.
147. Rees, H.A., Wilson, C., Doman, J.L., and Liu, D.R. (2019). Analysis and minimization of cellular RNA editing by DNA adenine base editors. *Sci. Adv.* 5, eaax5717. <https://doi.org/10.1126/SCIADV.AAX5717>.
148. Gaudelli, N.M., Lam, D.K., Rees, H.A., Solá-Esteves, N.M., Barrera, L.A., Born, D.A., Edwards, A., Gehrke, J.M., Lee, S.-J., Liguori, A.J., et al. (2020). Directed evolution of adenine base editors with increased activity and therapeutic application. *Nat. Biotechnol.* 38, 892–900. <https://doi.org/10.1038/s41587-020-0491-6>.
149. Renouf, B., Piganeau, M., Ghezraoui, H., Jasin, M., and Brunet, E. (2014). Creating cancer translocations in human cells using Cas9 DSBs and nCas9 paired nicks. *Methods Enzymol.* 546, 251–271. <https://doi.org/10.1016/B978-0-12-801185-0.00012-X>.
150. Bothmer, A., Phadke, T., Barrera, L.A., Margulies, C.M., Lee, C.S., Bucicchio, F., Moss, S., Abdulkarim, H.S., Selleck, W., Jayaram, H., et al. (2017). Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus. *Nat. Commun.* 8, 13905–13912. <https://doi.org/10.1038/ncomms13905>.
151. Petri, K., Zhang, W., Ma, J., Schmidts, A., Lee, H., Horng, J.E., Kim, D.Y., Kurt, I.C., Clement, K., Hsu, J.Y., et al. (2022). CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells. *Nat. Biotechnol.* 40, 189–193. <https://doi.org/10.1038/s41587-021-00901-y>.
152. Tao, J., Wang, Q., Mendez-Dorantes, C., Burns, K.H., and Chiarle, R. (2022). Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites. *Nat. Commun.* 13, 3685. <https://doi.org/10.1038/S41467-022-31322-3>.
153. Levesque, S., Mayorga, D., Fiset, J.P., Goupil, C., Düringer, A., Loïselle, A., Bouchard, E., Agudelo, D., and Doyon, Y. (2022). Marker-free co-selection for successive rounds of prime editing in human cells. *Nat. Commun.* 13, 5909. <https://doi.org/10.1038/S41467-022-33669-Z>.
154. Lovell-Badge, R., Anthony, E., Barker, R.A., Bubela, T., Brivanlou, A.H., Carpenter, M., Charo, R.A., Clark, A., Clayton, E., Cong, Y., et al. (2021). ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. *Stem Cell Rep.* 16, 1398–1408. <https://doi.org/10.1016/J.STEMCR.2021.05.012>.
155. Sharma, R., Dever, D.P., Lee, C.M., Azizi, A., Pan, Y., Camarena, J., Köhnke, T., Bao, G., Porteus, M.H., and Majeti, R. (2021). The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. *Nat. Commun.* 12, 472. <https://doi.org/10.1038/S41467-020-20792-Y>.
156. Ferrari, S., Beretta, S., Jacob, A., Cittaro, D., Albano, L., Merelli, I., Naldini, L., and Genovese, P. (2021). BAR-Seq clonal tracking of gene-edited cells. *Nat. Protoc.* 16, 2991–3025. <https://doi.org/10.1038/s41596-021-00529-x>.
157. Ludwig, L.S., Lareau, C.A., Ulirsch, J.C., Christian, E., Muus, C., Li, L.H., Pelka, K., Ge, W., Oren, Y., Brack, A., et al. (2019). Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics. *Cell* 176, 1325–1339. <https://doi.org/10.1016/J.CELL.2019.01.022>.
158. Uchida, N., Li, L., Nassehi, T., Donahue, R.E., Malech, H.L., and Tisdale Correspondence, J.F. (2021). Preclinical evaluation for engraftment of CD34 + cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models Demonstrate engraftment of gene-edited CD34 + cells in xenografts and non-human primates. *Cell Rep Med* 2. <https://doi.org/10.1016/j.xcrm.2021.100247>.
159. Ngom, M., Imren, S., Maetzig, T., Adair, J.E., Knapp, D.J.H.F., Chagraoui, J., Fares, I., Bordeleau, M.E., Sauvageau, G., Leboulch, P., et al. (2018). UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells. *Mol. Ther. Methods Clin. Dev.* 10, 156–164. <https://doi.org/10.1016/J.OMTM.2018.06.009>.
160. Zonari, E., Desantis, G., Petrillo, C., Boccalatte, F.E., Lidonni, M.R., Kajaste-Rudnitski, A., Aiuti, A., Ferrari, G., Naldini, L., and Gentner, B. (2017). Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy. *Stem Cell Rep.* 8, 977–990. <https://doi.org/10.1016/j.stemcr.2017.02.010>.
161. Naldini, L. (2019). Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. *EMBO Mol. Med.* 11. <https://doi.org/10.15252/emmm.201809958>.
162. Boitano, A.E., Wang, J., Romeo, R., Bouchez, L.C., Parker, A.E., Sutton, S.E., Walker, J.R., Flaveny, C.A., Perdew, G.H., Denison, M.S., et al. (2010). Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science* 329, 1345–1348. <https://doi.org/10.1126/science.1191536>.
163. Jackson, C.S., Durandt, C., Janse van Rensburg, I., Praloran, V., Brunet de la Grange, P., and Pepper, M.S. (2017). Targeting the aryl hydrocarbon receptor nuclear translocator complex with DMOG and Stemregenin 1 improves primitive hematopoietic stem cell expansion. *Stem Cell Res.* 21, 124–131. <https://doi.org/10.1016/J.SCR.2017.04.007>.
164. Casado, F.L. (2016). The Aryl Hydrocarbon Receptor Relays Metabolic Signals to Promote Cellular Regeneration. *Stem Cells Int.* 2016, 4389802. <https://doi.org/10.1155/2016/4389802>.
165. Fares, I., Chagraoui, J., Gareau, Y., Gingras, S., Ruel, R., Mayotte, N., Csaszar, E., Knapp, D.J.H.F., Miller, P., Ngom, M., et al. (2014). Pyrimidole derivatives are agonists of human hematopoietic stem cell self-renewal. *Science* 345, 1509–1512. <https://doi.org/10.1126/science.1256337>.
166. Fares, I., Chagraoui, J., Lehnertz, B., MacRae, T., Mayotte, N., Tomellini, E., Aubert, L., Roux, P.P., and Sauvageau, G. (2017). EPCR expression marks UM171-expanded CD34+ cord blood stem cells. *Blood* 129, 3344–3351. <https://doi.org/10.1182/blood-2016-11-750729>.

167. Hoggatt, J., Singh, P., Sampath, J., and Pelus, L.M. (2009). Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. *Blood* 113, 5444–5455. <https://doi.org/10.1182/blood-2009-01-201335>.
168. Watts, K.L., Adair, J., and Kiem, H.P. (2011). Hematopoietic stem cell expansion and gene therapy. *Cytotherapy* 13, 1164–1171. <https://doi.org/10.3109/14653249.2011.620748>.
169. Cutler, C., Multani, P., Robbins, D., Kim, H.T., Le, T., Hoggatt, J., Pelus, L.M., Despoints, C., Chen, Y.B., Rezner, B., et al. (2013). Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation. *Blood* 122, 3074–3081. <https://doi.org/10.1182/blood-2013-05-503177>.
170. Horwitz, M.E., Chao, N.J., Rizzieri, D.A., Long, G.D., Sullivan, K.M., Gasparetto, C., Chute, J.P., Morris, A., McDonald, C., Waters-Pick, B., et al. (2014). Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. *J. Clin. Invest.* 124, 3121–3128. <https://doi.org/10.1172/JCI74556>.
171. Piras, F., Riba, M., Petrillo, C., Lazarevic, D., Cuccovillo, I., Bartolaccini, S., Stupka, E., Gentner, B., Cittaro, D., Naldini, L., and Kajaste-Rudnitski, A. (2017). Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. *EMBO Mol. Med.* 9, 1198–1211. <https://doi.org/10.15252/emmm.201707922>.
172. Mazurier, F., Gan, O.I., McKenzie, J.L., Doedens, M., and Dick, J.E. (2004). Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. *Blood* 103, 545–552. <https://doi.org/10.1182/BLOOD-2003-05-1558>.
173. Walter, D., Lier, A., Geiselhart, A., Thalheimer, F.B., Huntscha, S., Sobotta, M.C., Moehrl, B., Brocks, D., Bayindir, I., Kaschutnig, P., et al. (2015). Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. *Nature* 520, 549–552. <https://doi.org/10.1038/NATURE14131>.
174. Ahuja, A.K., Jodkowska, K., Teloni, F., Bizard, A.H., Zellweger, R., Herrador, R., Ortega, S., Hickson, I.D., Altmeyer, M., Mendez, J., and Lopes, M. (2016). A short G1 phase imposes constitutive replication stress and fork remodelling in mouse embryonic stem cells. *Nat. Commun.* 7, 10660. <https://doi.org/10.1038/NCOMMS10660>.
175. Horn, P.A., Morris, J.C., Bukovsky, A.A., Andrews, R.G., Naldini, L., Kurre, P., and Kiem, H.P. (2002). Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. *Gene Ther.* 9, 1464–1471. <https://doi.org/10.1038/SJ.GT.3301820>.
176. Ito, K., Hirao, A., Arai, F., Matsuoka, S., Takubo, K., Hamaguchi, I., Nomiyama, K., Hosokawa, K., Sakurada, K., Nakagata, N., et al. (2004). Regulation of oxidative stress by ATM is required for self-renewal of hematopoietic stem cells. *Nature* 431, 997–1002. <https://doi.org/10.1038/NATURE02989>.
177. Jang, Y.Y., and Sharkis, S.J. (2007). A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. *Blood* 110, 3056–3063. <https://doi.org/10.1182/BLOOD-2007-05-087759>.
178. Rube, C.E., Fricke, A., Widmann, T.A., Fürst, T., Madry, H., Pfreundschuh, M., and Rube, C. (2011). Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. *PLoS One* 6, e17487. <https://doi.org/10.1371/JOURNAL.PONE.0017487>.
179. Yahata, T., Takanashi, T., Muguruma, Y., Ibrahim, A.A., Matsuzawa, H., Uno, T., Sheng, Y., Onizuka, M., Ito, M., Kato, S., and Ando, K. (2011). Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. *Blood* 118, 2941–2950. <https://doi.org/10.1182/BLOOD-2011-01-330050>.
180. Morganti, C., Cabezas-Wallscheid, N., and Ito, K. (2022). Metabolic Regulation of Hematopoietic Stem Cells. *Hemasphere* 6, e740. <https://doi.org/10.1097/HS9.0000000000000740>.
181. Pellin, D., Loperfido, M., Baricordi, C., Wolock, S.L., Montepeloso, A., Weinberg, O.K., Biffi, A., Klein, A.M., and Biasco, L. (2019). A comprehensive single cell transcriptional landscape of human hematopoietic progenitors. *Nat. Commun.* 10, 2395. <https://doi.org/10.1038/S41467-019-10291-0>.
182. Farlik, M., Halbritter, F., Müller, F., Choudry, F.A., Ebert, P., Klughammer, J., Farrow, S., Santoro, A., Ciaurro, V., Mathur, A., et al. (2016). DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation. *Cell Stem Cell* 19, 808–822. <https://doi.org/10.1016/J.STEM.2016.10.019>.
183. Dircio-Maldonado, R., Flores-Guzman, P., Corral-Navarro, J., Mondragón-García, I., Hidalgo-Miranda, A., Beltrán-Anaya, F.O., Cedro-Tanda, A., Arriaga-Pizano, L., Balvanera-Ortiz, O., and Mayani, H. (2018). Functional Integrity and Gene Expression Profiles of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells Generated In Vitro. *Stem Cells Transl. Med.* 7, 602–614. <https://doi.org/10.1002/SCTM.18-0013>.
184. Pietras, E.M. (2017). Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. *Blood* 130, 1693–1698. <https://doi.org/10.1182/BLOOD-2017-06-780882>.
185. McDermott, D.H., Gao, J.-L., Liu, Q., Siwicki, M., Martens, C., Jacobs, P., Velez, D., Yim, E., Bryke, C.R., Hsu, N., et al. (2015). Chromothrptic Cure of WHIM Syndrome. *Cell* 160, 686–699. <https://doi.org/10.1016/J.CELL.2015.01.014>.
186. Hou, Y., Gratz, H.P., Ureña-Bailén, G., Gratz, P.G., Schilbach-Stückle, K., Renno, T., Gungör, D., Mader, D.A., Malenke, E., Antony, J.S., et al. (2021). Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency. *Genes* 13, 35. <https://doi.org/10.3390/GENES13010035>.
187. Waisfisz, Q., Morgan, N.V., Savino, M., De Winter, J.P., van Berkel, C.G., Hoatlin, M.E., Ianzano, L., Gibson, R.A., Arwert, F., Savoia, A., et al. (1999). Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. *Nat. Genet.* 22, 379–383. <https://doi.org/10.1038/11956>.
188. Miyazawa, H., and Wada, T. (2021). Reversion Mosaicism in Primary Immunodeficiency Diseases. *Front. Immunol.* 12, 783022. <https://doi.org/10.3389/FIMMU.2021.783022>.
189. Blümich, S., Zdimerova, H., Münz, C., Kipar, A., and Pellegrini, G. (2021). Human CD34+ Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features. *Vet. Pathol.* 58, 161–180. <https://doi.org/10.1177/0300985820948822>.
190. Kamel-Reid, S., and Dick, J.E. (1988). Engraftment of immune-deficient mice with human hematopoietic stem cells. *Science* 242, 1706–1709. <https://doi.org/10.1126/SCIENCE.2904703>.
191. Aryee, K.E., Shultz, L.D., and Brehm, M.A. (2014). Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development. *Methods Mol. Biol.* 1185, 267–278. https://doi.org/10.1007/978-1-4939-1133-2_18.
192. Walsh, N.C., Kenney, L.L., Jangalwe, S., Aryee, K.E., Greiner, D.L., Brehm, M.A., and Shultz, L.D. (2017). Humanized Mouse Models of Clinical Disease. *Annu. Rev. Pathol.* 12, 187–215. <https://doi.org/10.1146/ANNUREV-PATHOL-052016-100332>.
193. Wen, R., Xu, C., Dong, C., Sheng, H., Zhao, L., Yang, Y., Zhang, A., Wang, S., Wang, L., Ju, Y., et al. (2021). Single-cell RNA sequencing reveals the landscapes of human cord blood hematopoietic stem cell differentiation during ex vivo culture. *Clin. Transl. Med.* 11, e616. <https://doi.org/10.1002/CTM2.616>.
194. Notta, F., Zandi, S., Takayama, N., Dobson, S., Gan, O.I., Wilson, G., Kaufmann, K.B., McLeod, J., Laurenti, E., Dunant, C.F., et al. (2016). Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. *Science* 351, aab2116. <https://doi.org/10.1126/SCIENCE.AAB2116>.
195. Mende, N., Bastos, H.P., Santoro, A., Mahbubani, K.T., Ciaurro, V., Calderbank, E.F., Quiroga Londoño, M., Sham, K., Mantica, G., Morishima, T., et al. (2022). Unique molecular and functional features of extramedullary hematopoietic stem and progenitor cell reservoirs in humans. *Blood* 139, 3387–3401. <https://doi.org/10.1182/BLOOD.2021013450>.
196. Belluschi, S., Calderbank, E.F., Ciaurro, V., Pijuan-Sala, B., Santoro, A., Mende, N., Diamanti, E., Sham, K.Y.C., Wang, X., Lau, W.W.Y., et al. (2018). Myelo-lymphoid lineage restriction occurs in the human haematopoietic stem cell compartment before lymphoid-primed multipotent progenitors. *Nat. Commun.* 9, 4100. <https://doi.org/10.1038/S41467-018-06442-4>.

197. Calvanese, V., Capellera-García, S., Ma, F., Fares, I., Liebscher, S., Ng, E.S., Ekstrand, S., Aguadé-Gorgorió, J., Vavilina, A., Lefaudeux, D., et al. (2022). Mapping human haematopoietic stem cells from haemogenic endothelium to birth. *Nature* 604, 534–540. <https://doi.org/10.1038/S41586-022-04571-X>.
198. Calvanese, V., Nguyen, A.T., Bolan, T.J., Vavilina, A., Su, T., Lee, L.K., Wang, Y., Lay, F.D., Magnusson, M., Crooks, G.M., et al. (2019). MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment. *Nature* 576, 281–286. <https://doi.org/10.1038/S41586-019-1790-2>.
199. Luff, S.A., Creamer, J.P., Valsoni, S., Dege, C., Scarfò, R., Dacunto, A., Cascione, S., Randolph, L.N., Cavalca, E., Merelli, I., et al. (2022). Identification of a retinoic acid-dependent haemogenic endothelial progenitor from human pluripotent stem cells. *Nat. Cell Biol.* 24, 616–624. <https://doi.org/10.1038/S41556-022-00898-9>.
200. Ditadi, A., Sturgeon, C.M., and Keller, G. (2017). A view of human haematopoietic development from the Petri dish. *Nat. Rev. Mol. Cell Biol.* 18, 56–67. <https://doi.org/10.1038/NRM.2016.127>.
201. Ivanovs, A., Rytbtsov, S., Ng, E.S., Stanley, E.G., Elefanty, A.G., and Medvinsky, A. (2017). Human haematopoietic stem cell development: from the embryo to the dish. *Development* 144, 2323–2337. <https://doi.org/10.1242/DEV.134866>.
202. Capo, V., Penna, S., Merelli, I., Barcella, M., Scala, S., Basso-Ricci, L., Draghici, E., Palagano, E., Zonari, E., Desantis, G., et al. (2021). Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis. *Haematologica* 106, 74–86. <https://doi.org/10.3324/HAEMATOL.2019.238261>.
203. Sakurai, M., Ishitsuka, K., Ito, R., Wilkinson, A.C., Kimura, T., Mizutani, E., Nishikii, H., Sudo, K., Becker, H.J., Takemoto, H., et al. (2023). Chemically defined cytokine-free expansion of human haematopoietic stem cells. *Nature* 615, 127–133. <https://doi.org/10.1038/s41586-023-05739-9>.
204. Bai, T., Li, J., Sinclair, A., Imren, S., Merriam, F., Sun, F., O’Kelly, M.B., Nourigat, C., Jain, P., Delrow, J.J., et al. (2019). Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel. *Nat. Med.* 25, 1566–1575. <https://doi.org/10.1038/s41591-019-0601-5>.
205. Piras, F., and Kajaste-Rudnitski, A. (2021). Antiviral immunity and nucleic acid sensing in haematopoietic stem cell gene engineering. *Gene Ther.* 28, 16–28. <https://doi.org/10.1038/s41434-020-0175-3>.
206. Rehwinkel, J., and Gack, M.U. (2020). RIG-I-like receptors: their regulation and roles in RNA sensing. *Nat. Rev. Immunol.* 20, 537–551. <https://doi.org/10.1038/S41577-020-0288-3>.
207. Motwani, M., Pesiridis, S., and Fitzgerald, K.A. (2019). DNA sensing by the cGAS-STING pathway in health and disease. *Nat. Rev. Genet.* 20, 657–674. <https://doi.org/10.1038/S41576-019-0151-1>.
208. Decout, A., Katz, J.D., Venkatraman, S., and Ablasser, A. (2021). The cGAS-STING pathway as a therapeutic target in inflammatory diseases. *Nat. Rev. Immunol.* 21, 548–569. <https://doi.org/10.1038/S41577-021-00524-Z>.
209. Sumner, R.P., Harrison, L., Touizer, E., Peacock, T.P., Spencer, M., Zuliani-Alvarez, L., and Towers, G.J. (2020). Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA. *EMBO J.* 39, e103958. <https://doi.org/10.15252/EMBJ.2019103958>.
210. Wienert, B., Shin, J., Zelin, E., Pestal, K., and Corn, J.E. (2018). In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway. *PLoS Biol.* 16, e2005840. <https://doi.org/10.1371/JOURNAL.PBIO.2005840>.
211. Karikó, K., Muramatsu, H., Ludwig, J., and Weissman, D. (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. *Nucleic Acids Res.* 39, e142. <https://doi.org/10.1093/nar/gkr695>.
212. Karikó, K., Muramatsu, H., Welsh, F.A., Ludwig, J., Kato, H., Akira, S., and Weissman, D. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol. Ther.* 16, 1833–1840. <https://doi.org/10.1038/MT.2008.200>.
213. Ihry, R.J., Worringer, K.A., Salick, M.R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018). P53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. *Nat. Med.* 24, 939–946. <https://doi.org/10.1038/s41591-018-0050-6>.
214. Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., and Taipale, J. (2018). CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. *Nat. Med.* 24, 927–930. <https://doi.org/10.1038/s41591-018-0049-z>.
215. Enache, O.M., Rendo, V., Abdusamad, M., Lam, D., Davison, D., Pal, S., Currimjee, N., Hess, J., Pantel, S., Nag, A., et al. (2020). Cas9 activates the p53 pathway and selects for p53-inactivating mutations. *Nat. Genet.* 52, 662–668. <https://doi.org/10.1038/s41588-020-0623-4>.
216. Wu, X., Dao Thi, V.L., Huang, Y., Billerbeck, E., Saha, D., Hoffmann, H.H., Wang, Y., Silva, L.A.V., Sarbanes, S., Sun, T., et al. (2018). Intrinsic Immunity Shapes Viral Resistance of Stem Cells. *Cell* 172, 423–438. <https://doi.org/10.1016/J.CELL.2017.11.018>.
217. Petrillo, C., Thorne, L.G., Unali, G., Schirolli, G., Giordano, A.M.S., Piras, F., Cuccovillo, I., Petit, S.J., Ahsan, F., Noursadeghi, M., et al. (2018). Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. *Cell Stem Cell* 23, 820–832. <https://doi.org/10.1016/j.stem.2018.10.008>.
218. Shi, G., Ozog, S., Torbett, B.E., and Compton, A.A. (2018). mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3. *Proc. Natl. Acad. Sci. USA* 115, E10069–E10078. <https://doi.org/10.1073/PNAS.1811892115>.
219. Ozog, S., Timberlake, N.D., Hermann, K., Garijo, O., Haworth, K.G., Shi, G., Glinkerman, C.M., Scheffer, L.E., D’Souza, S., Simpson, E., et al. (2019). Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes. *Blood* 134, 1298–1311. <https://doi.org/10.1182/BLOOD.2019000040>.
220. Kanter, J., Walters, M.C., Krishnamurti, L., Mapara, M.Y., Kwiatkowski, J.L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K.A., Pierciey, F.J., Bonner, M., et al. (2022). Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. *N. Engl. J. Med.* 386, 617–628. <https://doi.org/10.1056/NEJMoa2117175>.
221. Heffner, G.C., Bonner, M., Christiansen, L., Pierciey, F.J., Campbell, D., Smurny, Y., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2018). Prostaglandin E2 Increases Lentiviral Vector Transduction Efficiency of Adult Human Hematopoietic Stem and Progenitor Cells. *Mol. Ther.* 26, 320–328. <https://doi.org/10.1016/J.YMTHE.2017.09.025>.
222. Masiuk, K.E., Zhang, R., Osborne, K., Hollis, R.P., Campo-Fernandez, B., and Kohn, D.B. (2019). PGE2 and Poloxamer Synerpic F108 Enhance Transduction of Human HSPCs with a β -Globin Lentiviral Vector. *Mol. Ther. Methods Clin. Dev.* 13, 390–398. <https://doi.org/10.1016/J.OMTM.2019.03.005>.
223. Evans, M.E., Kumkhaek, C., Hsieh, M.M., Donahue, R.E., Tisdale, J.F., and Uchida, N. (2014). TRIM5 α variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo. *Mol. Ther.* 22, 348–358. <https://doi.org/10.1038/MT.2013.256>.
224. Cavazzana, M., Ribeil, J.A., Lagresle-Peyrou, C., and André-Schmutz, I. (2017). Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow’s Point of View. *Stem Cells Dev.* 26, 71–76. <https://doi.org/10.1089/SCD.2016.0230>.
225. Hübel, K. (2019). Mobilization and Collection of HSC. *The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies*, pp. 117–122. <https://doi.org/10.1007/978-3-030-02278-5>.
226. Canarutto, D., Tucci, F., Gattillo, S., Zambelli, M., Calbi, V., Gentner, B., Ferrua, F., Markt, S., Migliavacca, M., Barzaghi, F., et al. (2021). Peripheral blood stem and progenitor cell collection in pediatric candidates for ex vivo gene therapy: a 10-year series. *Mol. Ther. Methods Clin. Dev.* 22, 76–83. <https://doi.org/10.1016/J.OMTM.2021.05.013>.
227. Körbling, M., and Anderlini, P. (2001). Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? *Blood* 98, 2900–2908. <https://doi.org/10.1182/BLOOD.V98.10.2900>.

228. Scala, S. (2021). Haematopoietic reconstitution dynamics of mobilized peripheral blood- and bone marrow-derived haematopoietic stem/progenitor cells after gene therapy. *Hum Gene Ther* 23.
229. Steidl, U., Kronenwett, R., Rohr, U.P., Fenk, R., Kliszewski, S., Maercker, C., Neubert, P., Aivado, M., Koch, J., Modlich, O., et al. (2002). Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. *Blood* 99, 2037–2044. <https://doi.org/10.1182/BLOOD.V99.6.2037>.
230. Thornley, I., Nayar, R., Freedman, M.H., Stephens, D., Crump, M., Messner, H.A., and Sutherland, D.R. (2001). Differences in cell cycle kinetics of candidate engrafting cells in human bone marrow and mobilized peripheral blood. *Exp. Hematol.* 29, 525–533. [https://doi.org/10.1016/S0301-472X\(00\)00683-4](https://doi.org/10.1016/S0301-472X(00)00683-4).
231. Donahue, R.E., Kirby, M.R., Metzger, M.E., Agricola, B.A., Sellers, S.E., and Cullis, H.M. (1996). Peripheral Blood CD34+ Cells Differ From Bone Marrow CD34+ Cells in Thy-1 Expression and Cell Cycle Status in Nonhuman Primates Mobilized or Not Mobilized With Granulocyte Colony-Stimulating Factor and/or Stem Cell Factor. *Blood* 87, 1644–1653. <https://doi.org/10.1182/BLOOD.V87.4.1644.BLOODJOURNAL8741644>.
232. Sereni, L., Castiello, M.C., Marangoni, F., Anselmo, A., di Silvestre, D., Motta, S., Draghici, E., Mantero, S., Thrasher, A.J., Giliani, S., et al. (2018). Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation. *J. Allergy Clin. Immunol.* 142, 1272–1284. <https://doi.org/10.1016/J.JACI.2017.12.1000>.
233. Wilkinson, A.C., Dever, D.P., Baik, R., Camarena, J., Hsu, I., Charlesworth, C.T., Morita, C., Nakauchi, H., and Porteus, M.H. (2021). Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. *Nat. Commun.* 12, 686. <https://doi.org/10.1038/S41467-021-20909-X>.
234. Miccio, A., Cesari, R., Lotti, F., Rossi, C., Sanvito, F., Ponzoni, M., Routledge, S.J.E., Chow, C.M., Antoniou, M.N., and Ferrari, G. (2008). In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. *Proc. Natl. Acad. Sci. USA* 105, 10547–10552. <https://doi.org/10.1073/PNAS.0711666105>.
235. Ramírez, M.J., Pujol, R., Trujillo-Quintero, J.P., Minguillón, J., Bogliolo, M., Río, P., Navarro, S., Casado, J.A., Badell, I., Carrasco, E., et al. (2021). Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients. *Am. J. Hematol.* 96, 989–999. <https://doi.org/10.1002/AJH.26234>.
236. Gentner, B., and Naldini, L. (2019). Vivo Selection for Gene-Corrected HSPCs Advances Gene Therapy for a Rare Stem Cell Disease. *Cell Stem Cell* 25, 592–593. <https://doi.org/10.1016/J.STEM.2019.10.004>.
237. Aprile, A., Gulino, A., Storto, M., Villa, I., Beretta, S., Merelli, I., Rubinacci, A., Ponzoni, M., Markt, S., Tripodo, C., et al. (2020). Hematopoietic stem cell function in β -thalassemia is impaired and is rescued by targeting the bone marrow niche. *Blood* 136, 610–622. <https://doi.org/10.1182/BLOOD.2019002721>.
238. Tang, A., Strat, A.N., Rahman, M., Zhang, H., Bao, W., Liu, Y., Shi, D., An, X., Manwani, D., Shi, P., et al. (2021). Murine bone marrow mesenchymal stromal cells have reduced hematopoietic maintenance ability in sickle cell disease. *Blood* 138, 2570–2582. <https://doi.org/10.1182/BLOOD.2021012663>.
239. Crippa, S., Rossella, V., Aprile, A., Silvestri, L., Ravis, S., Scaramuzza, S., Pirroni, S., Avanzini, M.A., Basso-Ricci, L., Hernandez, R.J., et al. (2019). Bone marrow stromal cells from β -thalassemia patients have impaired hematopoietic supportive capacity. *J. Clin. Invest.* 129, 1566–1580. <https://doi.org/10.1172/JCI123191>.
240. Aprile, A., Sighinolfi, S., Raggi, L., and Ferrari, G. (2022). Targeting the Hematopoietic Stem Cell Niche in β -Thalassemia and Sickle Cell Disease. *Pharmaceuticals* 15, 592. <https://doi.org/10.3390/PH15050592>.
241. Park, S.Y., Matte, A., Jung, Y., Ryu, J., Anand, W.B., Han, E.Y., Liu, M., Carbone, C., Melisi, D., Nagasawa, T., et al. (2020). Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion. *Blood* 135, 2071–2084. <https://doi.org/10.1182/BLOOD.2019002227>.
242. Dalle Carbonare, L., Matte, A., Valenti, M.T., Siciliano, A., Mori, A., Schweiger, V., Zampieri, G., Perbellini, L., and De Franceschi, L. (2015). Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. *Blood* 126, 2320–2328. <https://doi.org/10.1182/BLOOD-2015-04-641969>.
243. Bogeska, R., Mikecin, A.M., Kaschnig, P., Fawaz, M., Büchler-Schäff, M., Le, D., Ganuza, M., Vollmer, A., Paffenholz, S.V., Asada, N., et al. (2022). Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. *Cell Stem Cell* 29, 1273–1284. <https://doi.org/10.1016/J.STEM.2022.06.012>.
244. Baldrige, M.T., King, K.Y., Boles, N.C., Weksberg, D.C., and Goodell, M.A. (2010). Quiescent haematopoietic stem cells are activated by IFN- γ in response to chronic infection. *Nature* 465, 793–797. <https://doi.org/10.1038/NATURE09135>.
245. Essers, M.A.G., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U., Duchosal, M.A., and Trumpp, A. (2009). IFN α activates dormant haematopoietic stem cells in vivo. *Nature* 458, 904–908. <https://doi.org/10.1038/nature07815>.
246. Catucci, M., Zanoni, I., Draghici, E., Bosticardo, M., Castiello, M.C., Venturini, M., Cesana, D., Montini, E., Ponzoni, M., Granucci, F., and Villa, A. (2014). Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity. *Eur. J. Immunol.* 44, 1039–1045. <https://doi.org/10.1002/EJI.201343935>.
247. Yuan, B., Zhou, X., Suzuki, K., Ramos-Mandujano, G., Wang, M., Tehseen, M., Cortés-Medina, L.V., Hernandez-Benitez, R., Moresco, J.J., et al. (2022). Wiskott-Aldrich syndrome protein forms nuclear condensates and regulates alternative splicing. *Nat. Commun.* 13, 5291. <https://doi.org/10.1038/S41467-022-31220-8>.
248. Martins, V.C., Busch, K., Juraeva, D., Blum, C., Ludwig, C., Rasche, V., Lasitschka, F., Mastitsky, S.E., Brors, B., Hielscher, T., et al. (2014). Cell competition is a tumour suppressor mechanism in the thymus. *Nature* 509, 465–470. <https://doi.org/10.1038/nature13317>.
249. Goyal, S., Tisdale, J., Schmidt, M., Kanter, J., Jaroscak, J., Whitney, D., Bitter, H., Gregory, P.D., Parsons, G., Foom, M., et al. (2022). Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. *N. Engl. J. Med.* 386, 138–147. <https://doi.org/10.1056/NEJM02109167>.
250. Philippidis, A. (2021). After Analysis, Bluebird Bio Says Vector “Very Unlikely” Cause of Acute Myeloid Leukemia. *Hum. Gene Ther.* 32, 332–334. <https://doi.org/10.1089/HUM.2021.29159.BFS>.
251. Hsieh, M.M., Bonner, M., Pierciey, F.J., Uchida, N., Rottman, J., Demopoulos, L., Schmidt, M., Kanter, J., Walters, M.C., Thompson, A.A., et al. (2020). Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. *Blood Advances* 4, 2058–2063. <https://doi.org/10.1182/BLOODADVANCES.2019001330>.
252. Kanter, J., Thompson, A.A., Pierciey, F.J., Hsieh, M., Uchida, N., Leboulch, P., Schmidt, M., Bonner, M., Guo, R., Miller, A., et al. (2023). Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. *Am. J. Hematol.* 98, 11–22. <https://doi.org/10.1002/AJH.26741>.
253. Jones, R.J., and DeBaun, M.R. (2021). Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. *Blood* 138, 942–947. <https://doi.org/10.1182/BLOOD.2021011488>.
254. Seminog, O.O., Ogunlaja, O.I., Yeates, D., and Goldacre, M.J. (2016). Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. *J. R. Soc. Med.* 109, 303–309. <https://doi.org/10.1177/0141076816651037>.
255. Brunson, A., Keegan, T.H.M., Bang, H., Mahajan, A., Paulukonis, S., and Wun, T. (2017). Increased risk of leukemia among sickle cell disease patients in California. *Blood* 130, 1597–1599. <https://doi.org/10.1182/BLOOD-2017-05-783233>.
256. Bernardo, M.E., and Aiuti, A. (2016). The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy. *Hum Gene Ther.* <https://doi.org/10.1089/hum.2016.103>.
257. Charlesworth, C.T., Hsu, I., Wilkinson, A.C., and Nakauchi, H. (2022). Immunological barriers to haematopoietic stem cell gene therapy. *Nat. Rev. Immunol.* 22, 719–733. <https://doi.org/10.1038/s41577-022-00698-0>.
258. Fumagalli, F., Calbi, V., Natali Sora, M.G., Sessa, M., Baldoli, C., Rancoita, P.M.V., Zamboni, A.A., Ciotti, F., Sarzana, M., et al. (2022).

- Lentiviral haematopoietic stem-cell gene therapy for early-onset meta-chromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. *Lancet* 399, 372–383. [https://doi.org/10.1016/S0140-6736\(21\)02017-1](https://doi.org/10.1016/S0140-6736(21)02017-1).
259. George, B.M., Kao, K.S., Kwon, H.S., Velasco, B.J., Poyser, J., Chen, A., Le, A.C., Chhabra, A., Burnett, C.E., Cajuste, D., et al. (2019). Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance. *Cell Stem Cell* 25, 185–192. <https://doi.org/10.1016/j.stem.2019.05.018>.
260. Chhabra, A., Ring, A.M., Weiskopf, K., Schnorr, P.J., Gordon, S., Le, A.C., Kwon, H.S., Ring, N.G., Volkmer, J., Ho, P.Y., et al. (2016). Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. *Sci. Transl. Med.* 8. <https://doi.org/10.1126/SCITRANSLMED.AAE0501>.
261. Griffin, J.M., Healy, F.M., Dahal, L.N., Floisand, Y., and Woolley, J.F. (2022). Worked to the bone: antibody-based conditioning as the future of transplant biology. *J. Hematol. Oncol.* 15. <https://doi.org/10.1186/S13045-022-01284-6>.
262. Ghannam, J.Y., Xu, X., Maric, I., Dillon, L., Li, Y., Hsieh, M.M., Hourigan, C.S., and Fitzhugh, C.D. (2020). Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. *Blood* 135, 1185–1188. <https://doi.org/10.1182/BLOOD.2019004001>.
263. Agarwal, R., Dvorak, C.C., Prockop, S., Kwon, H.-S., Long-Boyle, J.R., Le, A., Brown, J.W., Merkel, E., Truong, K., Velasco, B., et al. (2021). JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID). *Blood* 138, 554. <https://doi.org/10.1182/BLOOD.2021-153074>.
264. Pearse, B.R., McDonough, S.M., Proctor, J.L., Panwar, R., Sarma, G.N., Kien, L., Dushime, J., Adams, H.L., Hyzy, S.L., Brooks, M., et al. (2019). A CD117-Amanitin Antibody Drug Conjugate (ADC) Effectively Depletes Human and Non-Human Primate Hematopoietic Stem and Progenitor Cells (HSPCs): targeted Non-Genotoxic Conditioning for Bone Marrow Transplant. *Biol. Blood Marrow Transplant.* 25, S29–S30. <https://doi.org/10.1016/j.bbmt.2018.12.101>.
265. Omer-Javed, A., Pedrazzani, G., Albano, L., Ghaus, S., Latroche, C., Manzi, M., Ferrari, S., Fiumara, M., Jacob, A., Vavassori, V., et al. (2022). Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. *Cell* 185, 2248–2264. <https://doi.org/10.1016/j.cell.2022.04.039>.
266. Wang, H., Germond, A., Li, C., Gil, S., Kim, J., Kiem, H.P., and Lieber, A. (2022). In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4. *Blood Adv.* 6, 4360–4372. <https://doi.org/10.1182/BLOODADVANCES.2022007975>.
267. Felker, S., Shrestha, A., Bailey, J., Pillis, D.M., Siniard, D., and Malik, P. (2022). Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment. *JCI Insight* 7, e151847. <https://doi.org/10.1172/JCI.INSIGHT.151847>.
268. Hou, X., Zaks, T., Langer, R., and Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. *Nat. Rev. Mater.* 6, 1078–1094. <https://doi.org/10.1038/s41578-021-00358-0>.
269. Bessy, T., Itkin, T., and Passaro, D. (2021). Bioengineering the Bone Marrow Vascular Niche. *Front. Cell Dev. Biol.* 9, 645496. <https://doi.org/10.3389/FCCELL.2021.645496>.
270. Greener, J.G., Kandathil, S.M., Moffat, L., and Jones, D.T. (2022). A guide to machine learning for biologists. *Nat. Rev. Mol. Cell Biol.* 23 (23), 40–55. <https://doi.org/10.1038/s41580-021-00407-0>.
271. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Židek, A., Potapenko, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature* 596, 583–589. <https://doi.org/10.1038/s41586-021-03819-2>.
272. Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Židek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021). Highly accurate structure prediction for the human proteome. *Nature* 596, 590–596. <https://doi.org/10.1038/s41586-021-03828-1>.
273. Chen, W., Guillaume-Gentil, O., Rainer, P.Y., Gäbelein, C.G., Saelens, W., Gardeux, V., Klaeger, A., Dainese, R., Zachara, M., Zambelli, T., et al. (2022). Live-seq enables temporal transcriptomic recording of single cells. *Nature* 608, 733–740. <https://doi.org/10.1038/s41586-022-05046-9>.
274. Hoersten, J., Ruiz-Gómez, G., Lansing, F., Rojo-Romanos, T., Schmitt, L.T., Sonntag, J., Pisabarro, M.T., and Buchholz, F. (2022). Pairing of single mutations yields obligate Cre-type site-specific recombinases. *Nucleic Acids Res.* 50, 1174–1186. <https://doi.org/10.1093/NAR/GKAB1240>.
275. Lamsfus-Calle, A., Daniel-Moreno, A., Ureña-Bailén, G., Raju, J., Antony, J.S., Handgretinger, R., and Mezger, M. (2020). Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. *Blood Rev.* 40, 100641. <https://doi.org/10.1016/j.blre.2019.100641>.
276. Li, C., Wang, H., Georgakopoulou, A., Gil, S., Yannaki, E., and Lieber, A. (2021). Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model. *Mol. Ther.* 29, 822–837. <https://doi.org/10.1016/j.ymt.2020.09.001>.
277. Li, C., Georgakopoulou, A., Mishra, A., Gil, S., Hawkins, R.D., Yannaki, E., and Lieber, A. (2021). In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ -globin in β -YAC mice. *Blood Adv.* 5, 1122–1135. <https://doi.org/10.1182/BLOODADVANCES.2020003702>.
278. Li, C., Wang, H., Gil, S., Germond, A., Fountain, C., Baldessari, A., Kim, J., Liu, Z., Georgakopoulou, A., Radtke, S., et al. (2022). Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors. *Mol. Ther. Methods Clin. Dev.* 24, 127–141. <https://doi.org/10.1016/j.omtm.2021.12.003>.